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ABSTRACT
Smart drug delivery platforms such as designer liposomes can be used to enhance
medicinal properties by enabling control over the time and location of therapeutic
cargo release. This can be achieved by designing liposomes that respond to
different stimuli by releasing encapsulated contents. Specifically, this work
focuses on the synthesis of ion recognition lipid switches. These lipids are
designed such that their physical properties are altered upon chelation of a given
metal ion, in this case Zn2+, becoming membrane destabilizing upon molecular
recognition. This contributes to the current state of passively controlled release,
where pathophysiological conditions associated with a diseased site are used to
control spatiotemporal release of therapeutic cargo. The use of molecular
recognition events to effect conformational change and thus cargo release is a
newly emerging field of research. Here, a panel of zinc recognition lipids based
on known zinc chelating moieties including trispicoylamine (TPA) and N,N,N′,N′Tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) were synthesized and their
release potential analyzed. With incorporation into a liposome platform, these
lipids can be used to enhance the selectivity of release at diseased cells exhibiting
elevated zinc concentrations including ischemic tissues, neurodegenerative
diseases, and certain cancer types.3-8

iii

TABLE OF CONTENTS

Chapter One Lipids and Liposomes: Properties, Structures, and General
Information ............................................................................................................ 1
1.1.

General Structure and Properties of Lipids ............................................. 1

1.2.

Lipids in the Biological Setting ................................................................ 4

1.3.

The Liposome as a Drug Delivery Platform ............................................ 6

1.3.1. Liposome Formation ............................................................................ 6
1.3.2. Liposomal Surface Modifications ......................................................... 8
1.3.3. Active vs. Passive Release Mechanisms ........................................... 13
1.4. Summary and Implications ....................................................................... 20
Chapter Two Design and Synthesis of Ion Responsive Lipids for Controlled
Release Applications .......................................................................................... 22
2.1. Project Summary ...................................................................................... 22
2.2. The Biological Role of Zinc ....................................................................... 22
2.3. Molecular Recognition Events as Stimuli for Cargo Release via Lipid
Switches .......................................................................................................... 23
2.4. Design Inspiration and Considerations for Zinc Switchable Lipids ........... 26
2.5. Design and Synthesis of Zinc-Responsive Lipid ZnR1 ............................. 27
2.5.1. ZnR1 Synthesis ................................................................................. 27
2.5.2. Alternate Pathways to ZnR1 .............................................................. 30
2.5.3. Liposomal Release Studies with ZnR1 .............................................. 36
2.6. Design and Synthesis of Zinc-Responsive Lipids of ZnR2 Type .............. 38
2.6.1. Synthesis of ZnR2 Type Lipids .......................................................... 38
2.6.2. Liposomal Studies with ZnR2 Type Lipids ......................................... 41
2.7. Design and Synthesis of Zinc-Responsive Lipids of ZnR3 Type ............ 48
2.7.1. Synthesis of ZnR3 Type Lipids .......................................................... 50
2.8. Summary and Future Work ...................................................................... 52
2.9. Synthetic Details and Compound Characterization .................................. 53
iv

2.9.1. General Experimental Information ..................................................... 53
2.9.2. Synthetic Details: Z1 Compounds ..................................................... 54
2.9.3. Synthetic Details: Z2 Compounds ..................................................... 61
2.9.4. Synthetic Details: Z3 Compounds ..................................................... 64
List of References ............................................................................................... 68
Appendix ............................................................................................................. 76
Vita.................................................................................................................... 122

v

LIST OF ABBREVIATIONS
AMF

alternating magnetic field

AML

acute myeloid leukemia

Ar

argon

CaCl2

calcium chloride

CDCl3

deuterated chloroform

CPP

cell penetrating peptide

CuI

copper iodide

d

doublet

DAG

diacylglycerol

DCC

N,N'-Dicyclohexylcarbodiimide

DCM

dichloromethane

dd

doublet of doublets

DIBAL-H

diisobutylaluminium hydride

DMAP

4-dimethylaminopyridine

DMF

dimethylformamide

DOPE

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine

EDCI

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

EPR

enhanced permeability and retention effect

equiv

equivalent

EtOAc

ethyl acetate

EtOH

ethanol

Fab’

fragment of antigen binding

fM

femtomolar

FR

folate receptors

GUV

giant unilamellar vesicle

h

hours

H2

hydrogen

HER2

human epidermal growth factor receptor-2
vi

HNO3

nitric acid

J

coupling constant

K2CO3

potassium carbonate

KOH

potassium hydroxide

KOtBu

potassium tert-butoxide

LiCO3

lithium carbonate

LUV

large unilamellar vesicle

m

multiplet

M

molar

mAb

monoclonal antibody

MeCN

acetonitrile

MeOD

deuterated methanol

MeOH

methanol

mg

milligram

MgSO4

magnesium sulfate

MHz

megahertz

mL

milliliter

MLV

multilamellar vesicle

mM

millimolar

mmol

millimoles

MMP

matrix metalloproteinases

MT

metallothionein

N2

nitrogen

NaBH(OAc)3

sodium triacetoxyborohydride

NaBH4

sodium borohydride

NaCl

sodium chloride

NaHCO3

sodium carbonate

NaN3

sodium azide

NaOH

sodium hydroxide

NH4OAc

ammonium acetate
vii

nm

nanometer

NMR

nuclear magnetic resonance

ONB

o-nitrobenzyl

PA

phosphatidic acid

PBr3

phosphorus tribromide

PC

phosphatidylcholine

Pd(PPh3)4

Tetrakis(triphenylphosphine)palladium(0)

Pd/C

palladium on carbon

PdCl2(PPh3)2

Bis(triphenylphosphine)palladium(II) dichloride

PE

phosphatidylethanolamine

PEG

polyethylene glycol

PIPES

piperazine-N,N′-bis(2-ethanesulfonic acid)

PIPns

phosphatidylinositol polyphosphate family of isomers

PKCs

protein kinase Cs

pM

picomolar

PS

phosphatidylserine

pTsCl

para-Toluenesulfonyl chloride

quant

quantitative yield

quint

quintet

R8

octa-arginine

RES

reticulo-endothelial system

ROS

reactive oxygen species

rt

room temperature

s

singlet

S

shape parameter

siRNA

signaling ribonucleic acid

SOCl2

thionylchloride

sPLA2

secretory phospholipase A2

SUV

small unilamellar vesicle

t

triplet
viii

TAT

transactivator of transcription

TBS

tris buffered saline

TEA

triethylamine

THF

tetrahydrofuran

TLC

thin layer chromatography

TPA

Tris(2-pyridylmethyl)amine

TPEN

N,N,N’,N’,-Tetrakis(2-pyridylmethyl)ethylenediamine

UV

ultraviolet

ZIP

zinc importer protein

Zn(OAc)2

zinc acetate

ZnT

zinc transporter protein

μL

microliter

ix

LIST OF FIGURES
Figure 1. Lipid structure and shape properties. .................................................... 2
Figure 2. The structures of some biologically relevant lipids. ............................... 4
Figure 3. Surface modifications for increased efficiency of liposomal drug
delivery systems. ........................................................................................... 9
Figure 4. A schematic representation of stimuli responsive release of drug cargo
from liposomes. ........................................................................................... 14
Figure 5. Examples of pH responsive conformational lipid switches. ................. 18
Figure 6. Calcium triggered lipid switch ............................................................. 25
Figure 7. Zinc cheating molecules. .................................................................... 26
Figure 8. Proposed membrane disruption by zinc responsive lipid switches ..... 28
Figure 9. Synthesis of zinc lipid switch ZnR1 ..................................................... 29
Figure 10. Alternate synthetic pathway to lipid intermediate Z1.3. ..................... 31
Figure 11. Alternate pathways for the synthesis of lipid ZnR1 from common
intermediate Z1.3. ........................................................................................ 33
Figure 12. Alternative pathways to single pyridal tail units toward ZnR1. .......... 35
Figure 13. Structures of lipid targets ZnR2.1 – ZnR2.5. ..................................... 39
Figure 14. Synthetic steps toward ZnR2.1 ......................................................... 40
Figure 15. Synthesis of ZnR2.2 ......................................................................... 42
Figure 16. Optimal presentation of TPA core at the aqueous interface of the
liposomal membrane ................................................................................... 44
Figure 17. Dye release profile of lipid switch ZnR2.2 ......................................... 47
Figure 18. TPEN chelation of zinc and structures of lipid analogs ZnR3.1 –
ZnR3.4 ......................................................................................................... 49
Figure 19. Synthetic routes toward TPEN based lipid analogs .......................... 51

x

CHAPTER ONE
LIPIDS AND LIPOSOMES: PROPERTIES, STRUCTURES, AND
GENERAL INFORMATION
Lipids are unique biomolecular structures, each with a specific set of physical and
chemical properties.

Via their self-assembly into liposomes, lipids can be

harnessed for desired applications in molecular recognition and drug delivery.
Liposomes are advantageous on this front due to their controllable size, potential
for surface modifications, non-immunogenicity, and ability to solubilize multiple
drug types. First, we will discuss the general physical attributes of lipids and
biologically relevant lipids and their functions. Then, we will discuss the power of
the liposome as a drug delivery platform. Finally, we will dive into synthetic lipids
and their numerous applications.

1.1. General Structure and Properties of Lipids
Lipids are defined by their amphiphilic structures. When dispersed in aqueous
media, they spontaneously form aggregates driven by the disparity of polarities
that exist within the structure. Each lipid is composed of a polar (hydrophilic)
headgroup and a nonpolar (hydrophobic) tail region, as depicted in Figure 1.
Lipids have an overall shape based on the size ratio between these two sections
of the structure. Lipids with varying molecular shapes will form different selfassembled materials to maximize attractive properties when dispersed in
aqueous media.

The lipid shapes fall into one of three general categories:

cylinder, cone, or wedge. These shapes are calculated via the shape parameter
(S), as defined in equation 1.9 The shape of the lipid will determine its membrane
𝑆=

𝑐𝑟𝑜𝑠𝑠−𝑠𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑝𝑜𝑙𝑎𝑟 ℎ𝑒𝑎𝑑𝑔𝑟𝑜𝑢𝑝 𝑥 𝑙𝑖𝑝𝑖𝑑 𝑙𝑒𝑛𝑔𝑡ℎ
𝑙𝑖𝑝𝑖𝑑 𝑣𝑜𝑙𝑢𝑚𝑒

(Equation 1)

forming capabilities. The different lipid shapes and their resultant aggregate
formations are shown in Figure 1.

When lipids possess S=1, they exhibit

cylindrical shapes and are membrane forming with polar headgroups of
1

Figure 1. Lipid structure and shape properties.
a) The general structure of a lipid. Lipids are composed of (A) a hydrophobic tail
region consisting of alkyl tails with varying degrees of unsaturation (B) a linking
group between tail and head and (C) a polar head group. b) Lipid shapes and their
resultant aggregate and macrostructures when dispersed in aqueous media.
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approximately the same diameter as the lipid tails. When dispersed in aqueous
media, these lipids preferentially form bilayer materials including spherically
shaped liposomes. These lipid bilayers close themselves into vesicles in order to
maintain separation of their hydrophobic tails from the aqueous media which
forms an aqueous pocket inside of the lipid bilayer.

Lipid vesicles include

unilamellar vesicles, also called liposomes, and multilamellar vesicles, which are
large vesicles containing smaller vesicles within their aqueous core.

The

advantages and properties of these lipid vesicles will be discussed at length in a
future section.

When S>1, lipids take on a cone shape. These lipids have a larger headgroup
radius as compared to their tail area, and as a result favor assembly into micelles
in aqueous solution. Micelles lack the aqueous inner pocket of liposomes with
instead their inner layer being composed of the hydrophobic tails. However, they
operate under the same properties to shield their hydrophobic tails from aqueous
media. The final lipid shape is the inverted cone. These lipids possess a small,
usually highly charged, headgroup with a comparably large hydrophobic region,
giving them a shape parameter of S<1. The lipids in this category induce negative
curvature in a membrane environment, and preferentially self-assemble into
inverted micelles. Here, the hydrophilic headgroups form the inner core with the
hydrophobic tails extending outward and composing the outer layer. In the same
way that bilayers will self-assemble into liposomes to shield their hydrophobic tails
from aqueous conditions, inverted micelles will aggregate into an inverted
hexagonal phase structure, where multiple inverted micelles come together tailto-tail. This shields the outer hydrophobic layer of the inverted micelle from
aqueous conditions.

Of these three macrostructures, liposome, micelle,

hexagonal phase, the liposome presents the most interesting possibility as a drug
delivery platform due to the ability to manipulate their membrane properties. By
exploiting lipids of different shapes, membrane stability can be controlled and
utilized as a method of achieving cargo release. This property is at the core of
3

liposomal controlled release platforms, where switching from membrane forming
(S=1) to non-bilayer (S>1) lipids is the main method for the release of
encapsulated cargo.

1.2. Lipids in the Biological Setting
Natural lipids, those produced through biological processes, are key cell to viability.
They compose 50% of the mass of eukaryotic cellular membranes and are
responsible for the membrane structural integrity.10 It is the unique structure of
lipids that makes them suitable for membrane formation, as previously discussed.
Non-membrane supporting lipids, such as inverted cone shaped lipids, are also
present in the biological milieu, but only at lower percentages that don’t disturb
bilayer stability. These serve important and tightly regulated functions within the
cell as well. Natural lipids fall into two main categories, glycerophospholipids and
sphingolipids. These groups are determined by which molecule the lipids are
derived from, glycerol or sphingosine, respectively. Sterols, such as cholesterol,
are also grouped under the definition of lipids because they are also amphiphilic
membrane components, though they don’t follow the same general structure of
other lipids. Nevertheless, cholesterol is an abundant membrane component and

Figure 2. The structures of some biologically relevant lipids.
Polar headgroups for DAG, PA, PS, PIPns, PE, and PC are as shown.
Hydrophobic tail length and degree of saturation vary between each lipid. In
the PIPns isomer family, R can equal any combination of H or PO3-.
4

important to membrane integrity. Lipids dictate numerous processes in the cell,
performing structural and functional roles. The exact structures of natural lipids
dictate their function within the cell. The structures of some biologically relevant
lipids are shown in Figure 2. The variation in headgroup size and functionality
determines the function of each lipid. One of the most notable structural lipids is
phosphatidylcholine (PC).

PC is the most abundant lipid in eukaryotic cell

membranes and is the classical example of a cylindrical shaped lipid, favoring
bilayer formation. The remainder of the cellular membrane is composed of less
abundant lipids that exhibit functional roles within the cell, proteins, and other
membrane stabilizing molecules like cholesterol. PC is key to liposomal drug
delivery platforms as well, as it serves as a main bulk lipid for many of the lipid
formulations used to produce therapeutic liposomes.

Functional lipids, generally termed signaling lipids, represent the other branch of
lipids within the cell. Through recruitment of proteins to the membrane surface,
through either intra- or extra-cellular binding events, these lipids can regulate cell
activities controlling such processes as cell proliferation, apoptosis, metabolism,
gene expression, and membrane trafficking.11-13 The specific interactions between
lipids and proteins that mediate these processes can be as simple as a monovalent
binding event between a lipid and its target protein, or as complex as a
microdomain of lipids acting together to bind protein in a multivalent fashion. 14
These complex interactions recruit proteins to the cell surface and trigger a
cascade of important processes within the cell. Thus, aberrations in the interaction
of these vital signaling lipids with their corresponding peripheral proteins can lead
to the onset of diseases such as cancer, inflammation, autoimmunity, and
degenerative diseases.11, 15 These intricate interactions have led to a burgeoning
field involving the study of the activities of signaling lipids.

Many of the notable signaling lipids are glycerophospholipids including
diacylglycerol

(DAG),

phosphatidic

acid
5

(PA),

phosphatidylserine

(PS),

phosphatidylethanolamine

(PE),

and

phosphatidylinositol

polyphosphates

(PIPns).11, 15-16 DAG, the simplest of the signaling lipids, controls vital processes
within the cell. DAG activates protein kinase Cs (PKCs), enzymes that control the
cell cycle and exhibit tumor suppressing activity.17-19 PKC is one of the most highly
misregulated proteins in cancer. Thus, tightly regulated DAG activity is necessary
for the maintenance of human health. PA interacts with Raf-1, a kinase involved
in cancer.20 In healthy cells, PS is found mainly in the inner leaflet of the cellular
bilayer and is only translocated to the outer membrane leaflet, where it recruits
proteins, to signal apoptosis.21 PIPns regulate vesicular trafficking and modulate
lipid distribution within the cell by their interaction with lipid transfer proteins.22
Each of these regulatory functions of lipids help maintain a healthy cellular
environment.

Again, the abilities of these lipids to stabilize, destabilize, and

perform signaling roles within the cell are due to their specific shape and chemical
structure. This highlights the importance of lipid characteristics not only in the
biological setting, but when considering synthetically designed lipids.

1.3. The Liposome as a Drug Delivery Platform
Liposomes represent a key platform for delivery of drugs within a biological system.
They exhibit tunable properties in size, surface functionalization, cargo type,
surface charge, and release mechanism that allow for a customizable platform.
The properties of liposomes will be discussed below as they relate to their use as
a nanoscale drug delivery platform.
1.3.1. Liposome Formation
Lipids will self-assemble into vesicles when dispersed in aqueous media due to
their amphiphilic nature. While these arbitrarily formed vesicles are not formed
with homogeneous and predictable size or lamellarity, they can subsequently be
manipulated to be of uniform characteristics. A popular method for obtaining
liposomes of reliable size is through thin film formation, hydration, and extrusion.23
In this method, lipids in organic solvent are mixed in a defined ratio based on the
6

desired liposomal content. This lipid mixture is dried into a film, removing all
organic solvent from the sample. The film is then hydrated with water or an
aqueous buffer and subjected to freeze/thaw cycles to form large mulitilamellar
vesicles (MLVs) of various sizes. The solution of MLVs is subjected to extrusion
through polycarbonate filters with pores of the desired liposome diameter. Multiple
passes through the extrusion filter give liposomes of reliable size. Generally,
liposomes are composed of PC, the main bulk lipid of cell membranes. Other lipids
including synthetic analogs bearing desired properties or functionalities for the
specific liposomal platform can also be added to the film composition yielding
vesicles of desired lipid content.

Liposomes are formed in a variety of sizes depending on the desired application.
Utilizing different pore sizes in the extrusion step, or other less conventional vesicle
formation techniques24, liposomes of 20-1000 nm in diameter can be formed.
Small unilamellar vesicles (SUVs) are from 20-100 nm, large unilamellar vesicles
(LUVs) are greater than 100 nm in diameter, and giant unilamellar vesicles (GUVs)
are larger than 1000 nm in diameter. Generally, liposomes of 100-200 nm are
utilized for drug delivery applications.

Vesicles of this size have a higher

propensity to fuse with cell membranes due to the strain exerted on the lipids in
the highly curved liposome surface. They also benefit from an increased circulation
time by avoiding the reticulo-endothelial system (RES) longer than their larger
counterparts.24-25 Structures of this size are also able to make use of the enhanced
permeability and retention (EPR) effect. This effect arises since the vasculature
surrounding rapidly expanding cells, such as tumors, as well as other diseased
tissues like those in inflammatory diseases and ischemia, have loose junctions
between the endothelial cells of the blood vessel walls.

26-28

These gaps in the

vessel lining are 0.1-3 μM in size allowing nanosized structures to leak from the
blood vessel to the diseased area. A lack of drainage of lymphatic fluids, another
hallmark of the EPR effect, allows the leaked nanomaterials to remain at the
diseased site. However, the EPR effect only increases delivery 2-fold to tumor
7

sites versus other common accumulation organs.28 This makes the EPR effect,
on its own, not a powerful enough phenomenon to effect efficient drug delivery,
though it can be coupled with other modifications to increase liposomal delivery
and efficiency.

The ability of liposomes to encapsulate multiple drug types is also an attractive
factor in their use as a drug delivery platform. Liposomes can house hydrophobic
and hydrophilic cargo within the membrane bilayer or the aqueous core,
respectively. Prodrugs can also be incorporated via attachment to a synthetic lipid
at either the head group or as a hydrophobic tail, depending on the nature of the
drug. Further examples of this will be provided in the next section.
1.3.2. Liposomal Surface Modifications
Modifications to the surfaces of classical liposomes can drastically enhance their
power as a drug delivery vehicle. Surface modifications can act as shielding
groups to protect liposomes from clearance from the body. Other surface
modifications can increase the rate of fusion with target cells, while a very
important group of surface ligands is comprised of active targeting moieties to
enhance the selectivity for delivery to diseased cells within a complex biological
mixture. The main surface modifications are depicted in Figure 3. Multiple
surface modifications can be combined in one liposomal platform to enhance the
overall efficiency of the drug delivery system.
1.3.2.1. Surface Modifications for Creation of Stealth Liposomes
Synthetic modifications to bare liposomes can drastically enhance their power as
a drug delivery vehicle. Bare liposomes have a short half-life and are quickly
cleared from the bloodstream by the RES system.29 Though smaller liposomes
inherently have longer circulation times than larger vesicles, they still have
relatively short half-lives from an efficiency of drug delivery standpoint. Surface

8

Figure 3. Surface modifications for increased efficiency of liposomal
drug delivery systems.
Representative modifications for the creation of stealth liposomes, the increase
of liposome fusogenicity and cellular uptake, and actively targeted liposomes
are shown, though multiple modifications to effect each desired outcome are
available. Cellular penetrating peptides (CPPs), polyethyleneglycol (PEG),
monoclonal antibody (mAb) are shown as examples.

9

modifications can shield the liposome from clearance, thus increasing their halflife. These surface modifications act as a physical barrier to keep opsin proteins
from binding to the surface of the liposome, thus marking them for clearance by
the immune system.30

Initially, groups such as gangliosides and sialic acid

derivatives were used to decorate liposomes.25

These are common surface

markers found on red blood cells, so by mimicking the native cell population of the
administration route, the liposomes were able to evade the immune response.
Now, the most common stealth coating is polyethylene glycol (PEG). Incorporation
of PEG-PE conjugates into PC based liposomes showed an increase of circulation
half-life from 30 minutes for bare liposomes to 5 hours in the earliest studies in
PEGylation.31

PEGylation also decreases the leakiness of liposomes, better

harboring cargo for less off-site drug interactions.29-30

PEG incorporation is

relatively simple and there are now commercially available versions of lipids with
PEG of a range of molecular weights appended to the headgroup. 32 Advances in
PEGylation methods can now give circulation half-lives of 5-16 hours dependent
on PEG polymer length.29 PEG coatings can be purely polymer based or can be
terminated with a functional group for further synthetic modification to the cloaked
liposome surface. The impetus for this will be covered in the next section. Overall,
the size control and potential for surface modification of liposomes help to increase
circulation time and accumulation at diseased sites by evasion of the RES system
and taking advantage of the EPR effect.
1.3.2.2. Surface Modifications for Active Targeting with Liposomes
Liposomes can be decorated with a variety of small molecules to increase their
efficacy of delivery through active targeting. When based solely on the EPR effect,
liposomes only make it to the general vicinity of the target site.

Surface

modification with targeting groups will pull these liposomes to the surface of target
cells, increasing the therapeutic index of the delivery platform. Binding partners
with high affinity for ligands found overexpressed or solely expressed on the target
cell surface are ideal for targeting moieties. These groups can be appended
10

directly to the liposomal surface through functionalized lipids or attached to the
reactive end of a PEG-lipid conjugate present in the liposome formulation.
Presentation outside of the PEG shell effects greater targeting ability, while
shielding of the targeting moiety within the PEG shell protects the ligand from off
target binding outside of the desired location. Still dependent on the EPR effect,
once the small liposomes have leaked into the interstitial space of the diseased
tissue, recognition of the targeting group by the cell surface will trigger uptake or
fusion of the liposome. Induced removal of the PEG shell after arrival at the target
site can also aid in delivery, methods of which will be explained shortly. Ideally,
the liposome will fuse with the cell surface, dumping its molecular cargo into the
target cell or be taken in by endocytosis and then effect escape from the endosome
and cargo release.

Specially formulated fusogenic liposomes increase the

propensity of membrane-to-membrane fusion to effect cargo delivery while
avoiding the lytic activity of lysosomes.33

Another class of surface modification that instigates higher cellular uptake in a noncell-type specific manner are cell penetrating peptides (CPPs). CPPs are most
commonly highly cationic short peptides with transactivator of transcription (TAT)
and octa-arginine (R8) peptides as representative examples.34 These cationic
peptides function to enhance permeation of liposomal content into target cells.
Also, due to their ability to attenuate the surface charge of the liposome, drug
loading efficiencies for hydrophobic or negatively charged cargo such as siRNA
are increased with CPP decorated liposomes due to the increased electrostatic
interactions of these cargo with the surface CPP.34 CPPs can be rendered inactive
by enzyme removable or light cleavable groups.35-38 This allows the CPP to affect
its function only at the desired spatiotemporal location with application of the
correct stimulus. Spatiotemporal control of liposomal content delivery is a research
field of its own, and the work in this project contributes to that field.

11

Of heightened interest are the utilization of cell specific ligands for targeted
delivery. Folate receptors (FR) are over expressed in their functional form on
countless types of cancer cells, including ovary, breast, colon, lung, prostate, nose,
throat, and brain cancers.39 Also, metastatic cancers tend to express FRs at a
higher rate than non-metastatic cells.40 Likewise, FRs are also highly expressed
on macrophages involved in inflammatory and autoimmune diseases providing
multiple potential targets for folate mediated liposome therapies. 39 Folic acid
functionalized liposomes have been successfully applied for the co-administration
of multiple chemotherapeutics to FR expressing breast cancer cells.41 Many folate
mediated targeting methods have been successful for the preferred delivery of
drugs and imaging agents to cancerous, inflammatory and autoimmune diseased
cells.42-44 One interesting study demonstrated delivery of microbial epitopes to
cancer cells through folate receptor mediated delivery. Fusion of the tumor cell
with the therapeutic liposome led to expression of the epitopes on the cell surface,
activating the immune system causing cytotoxicity via complement mediated cell
lysis.45 Other surface markers that have been targeted by liposomal recognition
include CD123. This surface marker is overexpressed on acute myeloid leukemia
(AML) cells and increases cell resistance to apoptosis. Anti-CD123 monoclonal
antibodies (mAb) were appended to drug loaded PEGylated liposomes for
targeting. Specifically, liposomes that are targeted via mAb or antigen binding
fragments (Fab’) are termed immunoliposomes.46 Anti-CD123 immunoliposomes
were able to effect higher rates of cellular uptake and cytotoxicity versus
nontargeted liposomes.47 CD44 is a classic surface marker of cancer stem cells,
a subset of cancer cells that promote malignancy and therapeutic resistance.48
mAbs against CD44 have been integrated into immunoliposome platforms to
increase targeting and cytotoxicity against this potent cell type. 49

Human

epidermal growth factor receptor-2 (HER2) is another surface ligand of certain
cancer types that has been harnessed for targeted delivery via antibody mediated
processes.50 Essentially, any overexpressed ligand on a deleterious cell surface
12

has the potential to be targeted for more efficient therapeutic delivery of cargo via
active targeting liposomes.
1.3.3. Active vs. Passive Release Mechanisms
While liposomes are effective vehicles for transporting cargo due to their inherent
amphiphilic nature, the specific release of cargo at the desired location within the
body is key to an effective drug delivery vehicle. PEGylation, targeting ligands,
and modification with CPPs help to increase local concentration and fusogenicity
of liposomes, but do not directly effect a quick triggered release of drug. There
are, however, various methods to trigger cargo release from therapeutic
liposomes. These fall into two categories: active and passive release. Active
release relies on some form of external stimulus to effect release of molecular
cargo while passive release mechanisms utilize internal physiological stimuli, ie
conditions within the diseased tissue itself, to effect release.

A schematic

representation of triggered release mechanisms is shown in Figure 4. Whether
active or passive, these release mechanisms rely on one of a handful of methods
for release. These are membrane restructuring, deshielding of the liposome,
prodrug activation, lipid reconstruction, and conformational switching.
1.3.3.1. Active Release Mechanisms
Active release mechanisms require an input of some external stimulus. This is
advantageous in the fact that it limits off target release of cargo. However, external
stimuli can be limited by their ability to penetrate through healthy tissue to the
diseased area.

External stimuli are mainly reliant on photothermal effects,

including the application of light, heat, ultrasound, or a magnetic field to induce
release.

Light triggered release can be effected by a number of liposomal features.
Liposomes loaded with or appended with photosensitizers, such as porphyrin, can
increase the production of reactive oxygen species (ROS) upon application of light.
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Figure 4. A schematic representation of stimuli responsive release of drug cargo from liposomes.
Liposomes can be loaded with hydrophilic (green) or hydrophobic (purple) cargo in the aqueous core or lipid bilayer,
respectively. Prodrugs can also be bound to synthetic lipids at the headgroup as shown in yellow, or integrated as
a tail unit (not depicted here). Stimuli responsive lipids (red) can be incorporated for spatiotemporal control of drug
delivery. Upon application of stimuli (light, heat, ultrasound, pH change, enzyme, molecular recognition) the drugs
are release via membrane destabilization and/or prodrug activation.
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These ROS will oxidize any unsaturated points in the lipid tails. This makes the
lipid tails less hydrophobic, disrupting the membrane bilayer and effecting
release.51-53 Other methods of light triggered release rely on the light mediated
degradation of a lipid’s integrity, thereby disrupting the liposome. Photocleavable
groups can be incorporated into a synthetic lipid to induce degradation. In one
example,an o-nitrobenzyl (ONB) group was incorporated into a synthetic lipid tail.54
With application of 350 nm light, the ONB group was cleaved, yielding single tailed
lipids in the membrane, which are destabilizing to the liposomal integrity. Up to
80% cargo release of hydrophobic cargo was achieved via this method. These
both represent lipid reconstruction methods of drug release.

Photocleavable

groups can also be used to tether a prodrug to the liposomal surface. Again, upon
delivery of the liposome to the desired location a specific wavelength of light can
be applied locally to stimulate the release and activation of the drug from the
liposome surface.55 In this way, photochemistry can be utilized to deliver molecular
cargo from a number of loading sites of the liposome.

Similar to light reactivity, the application of heat itself can cause liposomal release.
Lipids have a specific phase transition temperature above which they become
more fluid. Phase transition temperatures are intrinsic to specific lipids, so required
temperatures to increase membrane fluidity of a given liposomal formulation can
be calculated. Localized heating of the diseased tissue will cause increased
membrane fluidity, enhancing membrane permeability and effecting release in that
area.56 Unfortunately, these phase transition temperatures are only a few degrees
above body temperature. While higher phase transition temperatures can be
achieved, the negative side effects associated with the therapeutic application of
higher temperatures are prohibitive.56 Other examples of thermal effects include
release through the destabilization of heat sensitive membrane incorporated
peptides or polymers and the degradation of encapsulated cargo into gaseous
components forming microbubbles.24,

57

One method to achieve increased

localized heating via external stimuli is through the addition of magnetic
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nanoparticles in the liposomal formulation. Under application of an alternating
magnetic field (AMF) the magnetic nanoparticles, generally iron based, will heat
up, giving upconverted localized heating of the liposomes. 24

Ultrasound

application can destabilize air pockets in the liposome, leading to their escape and
thus destabilization of the liposomal membrane, ie cargo release. 24 All of these
effects function under general membrane destabilization as their method of
release.

These represent spatiotemporal controlled external stimuli for drug

release via exogenous methods.

These mechanisms are hindered by the power of their stimulus. The depth of
penetration into living tissue for light, laser, heat or ultrasound require that the area
for treatment be close to the surface. This limits therapeutic applicability of these
systems to certain disease states. Deep tissue tumors, for example, would not be
treated efficiently through these methods. These stimuli can also have negative
effects on healthy cells. For example, UV light as a stimulus has the potential to
harm healthy cells peripheral to the target diseased tissue. For these reasons,
passive release mechanisms driven by the physiological differences between
diseased and healthy tissue provide a less invasive method for effecting release
at a desired point in the system.
1.3.3.2. Passive Release Mechanisms
In passive release, the stimulus for cargo release comes from the diseased tissue
itself. These stimuli are mainly changes from normal physiological conditions
associated with the target disease. Internal stimuli include lowered pH, increased
reducing environment, altered enzyme expression, and increased surface or
soluble molecule concentrations.

By designing a liposome platform that is

sensitive to these conditions, it will release therapeutic cargo only where these
altered physiological stimuli are present. These internal stimuli don’t suffer from
the tissue penetration and localization issues of active release mechanisms, as the
stimuli are inherently present at the diseased site. By spatiotemporal control of
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cargo release, the dose requirement can be lowered providing a more desirable
therapeutic index.

Passive release techniques are a powerful method for harnessing the unique
microenvironment of the targeted diseased tissue. Specialized synthetic lipids
have been designed to take advantage of these conditions. Lowered pH is one
hallmark of cancer cells. As tumor cells rapidly grow, blood vessel formation
throughout the new tissue is poorly controlled. This causes a hypoxic, or low
oxygen, environment in the tumor and surrounding tissues. To maintain their
growth in absence of sufficient oxygenation, tumor cells will switch to anaerobic
metabolic pathways causing an increase in the production of acidic metabolites
like lactic acid.58 This build up of acidic products causes a lower pH in cancerous
tissues as compared to healthy tissues. This difference in conditions can be
utilized as a trigger for selective release of drug cargo at the desired location.
Liposome formulations can effect cargo release under acidic conditions by a few
different mechanisms. The protonation of susceptible groups such as carboxylates
can change the electrostatic interactions of the polar headgroups of lipids in a
bilayer. By decreasing the charge balance in the polar section of the bilayer, there
is increased repulsion between headgroups and thus destabilization of the
membrane.59 This allows for the use of more classical lipids to effect release under
acidic conditions. Another avenue to acid triggered release is the implementation
of synthetic lipids that undergo a conformational change upon acidification.
Various trans-2-aminocyclohexanol based lipids have been prepared so that
protonation of the amino group causes a chair flip due to increased stabilization
via hydrogen bonding of the newly protonated amine (Figure 5).1,

60

In the

unprotonated chair structure, the alkyl tails were ideally arranged to insert into a
membrane, and after protonation the tails were maximally separated due to the
change in conformation from diequatorial to diaxial in respect to the tail
substitutions (Figure 5).

A di(methoxyphenyl)pyridine based lipid operated

similarly where protonation of the pyridine nitrogen led to hydrogen bonding of the
17

Figure 5. Examples of pH responsive conformational lipid switches.
a) A trans-2-aminocyclohexanol based lipid switch that undergoes a chair flip
upon protonation.1 b) A di(methoxyphenyl)pyridine based lipid switch that
undergoes extreme rotation at the headgroup upon protonation. 2 c) A
schematic depicting cargo release based upon conformational change lipid
switches.
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adjacent methoxy groups, which effected maximal separation of the alkyl tails.2
This changed the orientation of the alkyl tails to one another, increasing the cone
angle and disrupting the membrane. Acidic conditions can also be utilized to
deshield stealth liposomes.

PEGylated liposomes with acid sensitive linkers

between the PEG polymer chain and the liposomal surface have been developed.
These lipids were formed into vesicles with DOPE, which forms hexagonal phase
structures on its own favoring membrane fusion and cargo release. However, in
mixtures with PEG-lipid conjugates DOPE can form lamellar structures.61
Deshielding via the acidic environment revealed the fusogenic, destabilized DOPE
liposomal surface leading to a phase change from lamellar to hexagonal phase
and a release of contents. The induction of non-bilayer lipids, such as with this
method, is a common route for destabilization of liposomes for cargo release.
Here, this was achieved through the acid-catalyzed cleavage of vinyl ether,
diorthoester, and hydrazone linked PEG-PE conjugates.61-63 All of these release
examples were based on the destabilization of PE based liposomes after the
removal of the protective and stabilizing factor of the PEG coating.

Reducing conditions can also lead to drug release from liposomes based on
synthetic modifications to the liposome components such as the incorporation of
disulfide bonds. As with the acid sensitive method, disulfide linkages can be added
between cloaking PEG groups and the liposomal surface. Upon reduction of the
disulfide bond, the PEG layer is removed, destabilizing the liposomes and leading
to liposome aggregation and cargo release.64-66 Various other targeting moieties
have been coupled with this method, including CPPs such as TAT, whereby the
removal of the PEG polymer coating in the reductive environment of the diseased
tissue revealed TAT for increased uptake of the liposomes into cells, rather than
just destabilization based on the formation of hexagonal phase structures after
PEG removal.65
The overexpression of certain enzymes in diseased cell lines has also been
harnessed for targeted drug delivery. These enzymes include both intra- and
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extracellularly expressed enzymes. Lipids for this drug delivery platform have
been modified in similar ways to the other passive release techniques. That is,
enzymatic activity can effect drug release by a number of methods: destabilization
of the membrane through lipid restructuring, enzymatic removal of a polymer
(PEG) shielding layer, or activation of a prodrug via enzymatic cleavage. 67
Phospholipase sPLA2 can effect cargo delivery through the restructuring of PE.
Enzymatic cleavage of PE into lysoPE and stearic acid prompted membrane
destabilization and cargo release from liposomes composed of PE, PC, and
PEGylated PE. These were 2.5 times more potent than non-targeted liposomes.68
sPLA2 is upregulated in prostate, breast, and pancreatic cancers as well as
infections where the enzyme is excreted by several bacteria types.67 Lipid based
prodrugs where the enzymatically cleavable tail is replaced with a prodrug have
also been designed and applied. Various hydrophobic drugs were successfully
released via phospholipase cleavage of the prodrug. This method increases
encapsulation efficiency of lipophilic drugs as well as local concentration of drug
upon triggered release.67
The matrix metalloproteinases (MMPs) compose another family of enzymes
upregulated in cancer, where they are associated with angiogenesis.

MMPs

cleave specific peptide sequences, which can be incorporated into PEGylated
liposomes as a deshielding technique. MMP sensitive linkers were inserted as a
linker between PE and PEG as an effective means of dePEGylation at target tissue
sites. These specific liposomes also had mAb and CPP functionalities that were
revealed upon deshielding, providing a multitargeted platform for drug delivery.69
The ability to combine multiple shielding, deshielding, targeting, and release
triggers into a single liposomal platform is one of the desirable advantages to
liposomes as a drug delivery system.

1.4. Summary and Implications
Designer liposomes are utilized to control the spatiotemporal release of therapeutic
cargo by the incorporation of surface modifications and/or synthetic lipid analogs
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into the liposomal composition. These modifications serve to increase circulation
time, provide a targeted accumulation of therapeutic liposomes at diseased cells,
and trigger release of drug cargo at the desired time and location. Currently,
release from liposomes can be controlled via active (external) or passive (internal)
stimulus as summarized above. Many of these methods rely on the production of
non-bilayer lipids as the means of membrane destabilization to effect release.
Passive release techniques present a unique situation where the characteristics of
diseased cells can be harnessed to trigger the release of drugs or therapeutic
cargo. Current work in this area relies mainly on pH differences between healthy
and cancerous cells to trigger a membrane change and effect release. Molecular
recognition events would hypothetically create a more specific release potential
based on the concentrations of metabolites, enzymes, ions, or other biomolecules
that are unique to the target site. This work seeks to utilize molecular recognition
of increased ion concentrations to differentiate between healthy and diseased
cells. These molecular recognition events will cause the bound lipid analog to
undergo a conformational change leading to destabilization of the liposome
membrane and thus leakage of encapsulated cargo. Currently, no controlled
release strategies have been approved for clinical use, thus advances in controlled
release platforms would contribute to the current toolbox of available liposomal
release tactics expanding the applicability of liposomes to treat various diseases.
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CHAPTER TWO
DESIGN AND SYNTHESIS OF ION RESPONSIVE LIPIDS FOR
CONTROLLED RELEASE APPLICATIONS
2.1. Project Summary
The goal of this project is to synthesize a panel of lipid switches for zinc recognition.
These lipids, upon binding of Zn2+, will undergo a conformational change proposed
to shift the lipid shape from a membrane supportive structure to a non-bilayer lipid
leading to the destabilization of the surrounding membrane environment.

By

including these lipid switches in liposomal formulations, we can control membrane
stability, and by extension content release, based on the ion concentration of the
surrounding media. This platform is of specific interest for delivery of therapeutic
cargo to diseased tissues in which local zinc concentrations are elevated including
ischemic tissues, neurodegenerative diseases, and certain cancer types. 3-8
Through this platform, we propose to harness a physiological difference between
healthy and diseased tissues, creating a new passive release technology.

2.2. The Biological Role of Zinc
Zinc is an essential element present at trace amounts in the human body. The
bulk of zinc is bound to proteins, with approximately 10% of all human proteins
containing zinc in its bound state.70 In these proteins it plays structural and
catalytic roles, being involved in the function of approximately 300 different
enzymes.71 The remaining minor fraction of zinc exists as its labile ion form. Free
zinc is present at very low concentrations within the cytosol of cells, at estimated
subnanomolar concentrations. The bulk of free zinc is tightly regulated in storage.
Zinc importer proteins (ZIP) and zinc transporter proteins (ZnT) act to shuttle zinc
in and out of the cytosol, respectively. These proteins are present in the cellular
membrane as well as vesicular membranes including those of storage vesicles,
endoplastic recticulum, mitochondira, and the golgi where they shuttle excess zinc
for storage.3 Zinc that is not stored in these subcellular compartments is buffered
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by reversible binding to metallothionein (MT), a metal binding protein that will
release free zinc upon receiving the appropriate signal.72-73

Free zinc

concentrations are increased in neuronal cells undergoing apoptosis as a
consequence of ischemia or trauma in the brain.3 Zinc dysregulation is also
involved in certain cancers.4-6 Chelation therapies have been applied for the
treatment of Alzheimer’s disease, further providing that zinc is a worthy target for
a therapeutic platform.7-8 In this work, a lipid switch will be designed so that upon
recognition of Zn2+ conformational changes will drive cargo release.

2.3. Molecular Recognition Events as Stimuli for Cargo Release
via Lipid Switches
This work specifically focuses on the utilization of lipid switches as a cargo release
tactic, a newly developing approach based on the molecular recognition of
upregulated ions or metabolites to effect cargo release from a liposome. This
research will serve to expand the current available toolbox of controlled release
tactics which is currently limited. Various physiological stimuli for cargo release
have been discussed thus far, and while ion recognition falls into that category, it
will be covered in detail now. Lipid switches, similar to the conformational release
lipids discussed in the pH responsive section, rely on membrane destabilization to
effect release. Recognition of the target molecule by a synthetic lipid switch leads
to a conformational change of the lipid and thus a change in its membrane support
characteristics.

This method has been applied for the recognition of

overexpressed surface markers of cancer cells, altered membrane compositions,
and upregulated ion concentrations in diseased cells.74-76 A boronic acid lipid was
synthesized for molecular recognition of carbohydrates, which are overexpressed
on cancer cell surfaces. Liposomes containing this molecular recognition lipid
were shown to bind and enhance cellular delivery.76

Liposomal membrane

restructuring via multivalent recognition of carbohydrate moieties was the primary
method of cargo delivery, where increased movement of the recognition lipid within
the membrane caused increased membrane permeability.
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Ion

recognition

events

are

another

interesting method for

membrane

destabilization. For example, a calcium-responsive lipid switch was designed such
that upon calcium chelation the lipid underwent a conformational change from
membrane supportive to membrane destabilizing. Here, a previously described
calcium sensor77 was modified to suit the lipid requirement for membrane insertion.
Alkyl tails were appended to the calcium sensor rather than a fluorescent indicator
as in the original sensor. Through chelation with the carboxylate moteifs present
at the lipid head, binding dependent cargo release was achieved (Figure 6) .74 The
lipid switches including the pH responsive examples discussed in section 1.3.4.2.
undergo similar conformational changes where protonation and hydrogen bonding
can be considered a type of molecular recognition.1-2, 60 Specific to the interest of
this work, other ion responsive lipids have been seen in literature as well. These
include copper and zinc responsive lipid switches. A bispidinone based lipid was
utilized to recognize copper via electrostatic interactions between nitrogens and
Cu2+, effecting a boat-to-chair conformational change at the headgroup causing
convergence of the alkyl tails. Even though the tails became less distanced from
one another via this chelation event, release was still seen with the application of
Cu2+. This shows that perturbation of the membrane in general by conformational
changes may be enough of a driving force for efficient cargo release. A final
example on ion chelation operates slightly differently than the previous examples.
Dimeric zinc chelates of a sugar based lipid preferentially formed liposomes, where
treatment of liposomes containing the zinc chelate with acid caused removal of the
zinc from complexation via protonation, which effected cargo release. 78 These
pre-complexed lipids were found to increase delivery of internalized cargo to
gastric cancer cells, based on the inherent acidity of cancerous tissues.
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Figure 6. Calcium triggered lipid switch
Lipid switch based on a fluorescent calcium sensor, indo-1. Titration with Ca2+
effected 65% release of hydrophobic dye nile red from liposomes containing 10%
of Indo-lipid with PC comprising the remainder of the membrane.
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2.4. Design Inspiration and Considerations for Zinc Switchable
Lipids
In regards to the design of a zinc responsive lipid switch, we drew inspiration from
previous work with the study of zinc chelating molecules. Trispicoylamine (TPA)
and N,N,N′,N′-Tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) are two wellknown zinc chelators (Figure 7). They bind zinc with high affinity with dissociation
constants of 10 pM and 0.3 fM, respectively.79 Also, these chelating groups bind
preferentially to zinc over other biologically available divalent transition metal
cations such as iron or manganese, as predicted by the Irving-Williams series.79-80
These nitrogen based chelators vary in the pKa of their central tertiary nitrogens,
wherein TPA exhibits a pKa of 6.17 and TPEN has a pKa 7.19. This makes TPA
less likely to be protonated at physiological pH, resulting in more operational
chelator available in the biological setting.79 These pyridal core structures have
been utilized to visualize zinc concentrations in live cells and tissues. 81-84 By
appending a fluorescent molecule to the general TPA structure, a fluorescence
turn on effect was seen following the chelation of zinc (using Zinpyr-1, Figure 7).

Figure 7: Zinc cheating molecules.
Structures of pyridal zinc chelating molecules TPA and TEPN. Zinpyr-1 is a
flurosecence turn-on probe for the detection of zinc in solution or the biological
setting.
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For our purposes, we do not require a fluorescent indicator. We instead envision
using the chelator core structure as the polar headgroup of a lipid. Rigidly attached
tails will build in the conformational change aspect that is required of the lipid and
thus effect release of cargo upon binding of zinc to the chelating lipid core (Figure
8). In this manner we will be able to control membrane stability and by extension
cargo delivery based on membrane composition of the given liposome. In the next
sections, synthesis of lipids based on these design principles will be discussed.

2.5. Design and Synthesis of Zinc-Responsive Lipid ZnR1
2.5.1. ZnR1 Synthesis
Zinc responsive lipid ZnR1, Figure 9, was the original design for a zinc triggered
lipid. In this structure, a TPA core is appended with three alkyl tails attached via
amide linkages. These tails are attached at the 4-position of the pyridine subunit,
allowing the alkyl tails to rest comfortably within a membrane bilayer when in the
unbound state.

Synthesis of ZnR1 (Figure 9) began with the diesterification of commercially
available 2,4-pyridinedicarboxylic acid.

This acid catalyzed ester formation

quantitatively gave intermediate Z1.1.85 This diester intermediate then underwent
a selective reduction with sodium borohydride to give aldehyde Z1.2.86

The

aldehyde functionality was utilized to perform successive reductive aminations in
a one pot approach, yielding the TPA core bearing three pyridine esters in a 49%
yield as intermediate Z1.3.87 This gave the TPA core in good yield over few steps,
as compared to previous attempts to form the TPA core via successive SN2
substitution reactions (see further discussion below).

The addition of the amide tails was approached from a number of synthetic angles.
The necessity of repeated additions to the trifunctionalized core was a stumbling
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Figure 8. Proposed membrane disruption by zinc responsive lipid
switches
Lipid targets ZnR2.2 (panel a, TPA based) and ZnR3.1 (panel c, TPEN based)
are depicted in their unbound state, inserted comfortably into the membrane
bilayer. Upon treatment with Zn2+, the lipid switches are proposed to bind zinc in
a 1:1 ratio to give ZnR2.1-Zn2+ (panel b) and ZnR3.1-Zn2+ (panel d). The lipid
switches are designed such that they take on non-bilayer lipid shapes upon
binding with zinc. e) A schematic representation of the unbound lipid switches
(blue) in a stable liposome and membrane destabilization caused by titration with
zinc forming zinc-bound lipids (red) that have undergone the proposed
conformational change.
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Figure 9. Synthesis of zinc lipid switch ZnR1
Conditions: i) TsOH, EtOH, reflux ii) DIBAL-H, -78°C, dry THF iii) NH4OAc,
NaBH(OAc)3, dry DCM iv) dodecylamine, DIBAL-H, dry THF, 0°C→ R.T. then
Z1.3
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block.

While more traditional methods were originally pursued, ultimately an

aminolysis of the ester groups was utilized. This was accomplished by activation
of the tail precursor dodecylamine with DIBAL-H. Usually, DIBAL-H is used as a
reducing agent. Here, as exemplified in the work by Huang et al where they
prepared a number of ethylbenzoate derivatives via organometallic complexes of
various amines with DIBAL-H, it is used to activate an amine for aminolysis of an
ester.88 This was key to overcoming previous complications with the addition of the
tails.

Other synthetic approaches involved proceeding through a hydrolyzed

intermediate of the triester Z1.3. This intermediate, bearing three carboxylic acid
functionalities, was very polar causing solubility issues as well as problems in the
purification of said intermediate (see further discussion below). By utilizing these
aminolysis conditions, we were able to bypass that troubled intermediate and
proceed directly to the desired amide. This reaction also utilized an excess of a
very reactive species, the organometallic complex, leading to full conversion of the
triester to triamide, which was key to completion of this synthesis, as other
synthetic methods, described below, failed to effect conversion of all three tail
precursor units to the desired amide bonds. All of these considerations together
led to the aminolysis method being an overall better route to pursue for completion
of the target lipid.
2.5.2. Alternate Pathways to ZnR1
In the pursuit of lipid ZnR1, many synthetic routes were taken. Alternate pathways
yielding interesting intermediates are given below. These attempts were focused
on either first constructing the TPA core and then adding the alkyl tail units, or vice
versa.

An alternate attempt to synthesize triester compound Z1.3 (Figure 10) was aimed
at forming the TPA core via successive SN2 substitutions to synthesize the central
tertiary amine. This approach was hindered by the instability of intermediates
containing a leaving group at the pseudo-benzylic position of the pyridine subunits
30

Figure 10. Alternate synthetic pathway to lipid intermediate Z1.3.
Conditions: i) NaBH4, CaCl2, 0°C, degassed EtOH ii) PBr3, dry DCM iii) p-TsCl,
TEA, DMAP, dry DCM iv) NaN3, dry DMF, 85°C v) 10% Pd/C, H2, EtOAc vi) Z1.5
(or Z1.6), LiCO3, dry DCM
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which led to no quantifiable conversion of these intermediates to the desired
tertiary amine core. These synthetic approaches will be discussed next.

The alternative synthesis of intermediate Z1.3 began with a selective reduction of
intermediate Z1.1. The diester was selectively reduced at the 2-position adjacent
to the pyridine nitrogen through the use of CaCl2 to chelate that specific ester. This
allowed for the selective reduction to an alcohol at the 2-position over the other
available ester at the 4-position.85

This reduction proceeded well to give

intermediate Z1.4. The alcohol functionality was then transformed to a leaving
group as bromine or tosylate in intermediates Z1.5 and Z1.6, respectively. To
install the necessary nitrogen into the organic skeleton, a substitution reaction with
sodium azide quantitatively gave intermediate Z1.7, which was reduced to primary
amine Z1.8 through palladium catalyzed hydrogenation. Then, the primary amine
of compound Z1.8 was reacted with two equivalents of either compound Z1.5 or
Z1.6 to target triester Z1.3. This final successive SN2 reaction was not successful
due to the instability of intermediates with a leaving group at the pseudo benzylic
position of the pyridine ring. This led to poor to no conversion to target compound
Z1.3. It was then that the reductive amination pathway as described in the previous
section was designed and pursued successfully, effectively bypassing the unstable
intermediates and shortening the overall synthesis of Z1.3 from 6 to 3 steps.

With intermediate Z1.3 in hand, a number of methods for incorporating the alkyl
tails were considered (Figure 11). The most classical way to construct an amide
bond is through the activation of a carboxylic acid precursor with carbodiimide
chemistry and subsequent attack by an amine yielding the desired amide bond.
The required carboxylic acid precursor, Z1.9, proved difficult to purify and collect
due to the polarity of the three carboxylic acid moieties within the molecule. This
led to a thorough search of the literature to devise a new tactic for the incorporation
of the three alkyl tail units. Kim et al published the direct amidation of various
esters including ethyl isonicotinate with aromatic and aliphatic amines in the
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Figure 11. Alternate pathways for the synthesis of lipid ZnR1 from common intermediate Z1.3.
Conditions: i) 2 M KOH, THF, 100°C ii) DCC, dodecylamine, DMAP iii) 1) SOCl 2, DCM 2) Dodecylamine, TEA, dry
THF iv) KOtBu, dodecylamine, THF
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presence of KOtBu under a proposed peroxide mediated mechanism.89 These
were achieved in good yields over short time periods, 5-60 minutes in most cases.
However, the application of these conditions to triester Z1.3 did not yield the
desired amide bonds. Next, an acid chloride version of Z1.3 was targeted to
increase the reactivity of the carbonyl groups. To this end, intermediate Z1.3 was
converted to carboxylic acid Z1.9 by refluxing with KOH and used without
purification beyond an extractive workup. The triacid chloride was prepared and
used directly for the next reaction without characterization. Full conversion of Z1.9
to acid chloride was monitored by the disappearance of the starting material spot
(Z1.9) via TLC. Subsequent reaction with dodecyl amine did not provide the target
compound ZnR1. Possible pitfalls of this avenue include the presence of three
reactive or highly polar carbonyl groups attempting to couple with a long chain
saturated amine causing solubility issues along with the inability to purify these
highly polar intermediates. Ultimately, due to the combination of these issues, a
new approach was devised to incorporate the three alkyl tail units. It was here that
the aminolysis conditions utilizing DIBAL-H described in section 2.5.1 were applied
successfully.

Concurrent with the previously described syntheses, attempts to construct
individual pyridine tail units and then trimerize them were also considered (Figure
12). Again, the classical approach of carbodiimide coupling was pursued first.
First, the ester of intermediate Z1.4 was hydrolyzed to give carboxylic acid
intermediate Z1.10. This was coupled via carbodiimide chemistry with dodecyl
amine. However, this was unsuccessful and did not yield intermediate Z1.11. The
direct amidation with KOtBu conditions as given in the last section were applied to
both intermediates Z1.4 and Z1.2. The reaction with Z1.4 yielded only starting
materials without conversion to product. This was most likely due to the potassium
tertbutoxide deprotonating the alcohol rather than interacting with the ester
functional group was required for the desired transformation. Application of the
same conditions to Z1.2 also did not yield the desired product, however the
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a)

b)

Figure 12. Alternative pathways to single pyridal tail units toward ZnR1.
a) Formation via classical carbodiimide chemistry. Conditions: i) 2 M KOH, THF,
100°C ii) EDCI, dodecylamine, DMAP, dry DMF b) Formation of amide bond via
direct amidation led to the hemiaminol Z1.14 rather than desired intermediate
Z1.13. Conditions: iii) 1) SOCl2, DCM 2) dodecylamine, TEA, dry THF
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attempted conversion of Z1.2 to an acid chloride and subsequent substitution with
dodecyl amine gave interesting results (Figure 12). The desired single tailed
aldehyde Z1.12 was not formed, instead the hemiaminol Z1.13 was recovered.
This was due to the conversion of the aldehyde unit to a geminal halohydrin and
subsequent substitution of the chloride with dodecyl amine. Attempts to reverse
the hemiaminol and eliminate the long chain amine were not successful and
although this was not the desired outcome it did reveal the possibility for reactivity
through this particular mechanism at the pyridal ethyl ester position, which could
be useful information for future synthetic endeavors. It also supports the notion
that previous TPA intermediate Z1.9 was probably the issue with the syntheses
laid out in Figure 11, as the desired ester hydrolysis reaction was able proceed
through a single version of the ester intermediate (Z1.4, Figure 12). Through the
investigation of parallel synthetic routes, the formation of triester intermediate Z1.3
and direct conversion to ZnR1 via the aminolysis reaction described above
provided the shortest and most straightforward route for the synthesis of the
desired lipid.
2.5.3. Liposomal Release Studies with ZnR1
With lipid target ZnR1 successfully synthesized, next began liposomal release
experiments. Liposomes containing 0, 10, and 20% of ZnR1 were investigated for
their triggered release potential.
For all experiments, liposomes were formed via the thin film hydration method. 23
Stock solutions of lipids ZnR1 (5mM), PC (32mM), and hydrophobic dye nile red
(5mM) were prepared in chloroform, with ZnR1 in a 1:1 mixture of chloroform and
methanol. Lipids were aliquoted to clean, dry vials to prepare the desired lipid
ratios at 2mM total lipid content. For example, to create liposomes containing 10%
ZnR1 lipid, 13.3 μL of PC stock, 10 μL of ZnR1 stock, and 5 μL of nile red stock
were combined in a clean, dry vial. The resulting solution was dried under a stream
of nitrogen until all solvent was removed. The vial containing the lipid film was
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then dried further under high vacuum to assure complete removal of residual
solvent. Then, 250 μL of MilliQ purified water was added to the vial and the film
was hydrated at 60°C for 45 minutes with vortexing every 15 minutes.

The

resulting liposome solution was put through ten freeze-thaw cycles with a dry
ice/acetone bath and 60°C water bath. This gave a solution of non-uniform size
or lamellarity vesicles which were then extruded 15 times through a 200 nm
polycarbonate membrane to yield a solution of 200 nm diameter liposomes
encapsulating nile red. These same methods of thin film hydration and extrusion
were used to prepare all liposomes for this work.

To determine the release profile of ZnR1, prepared liposomes were titrated with
Zn2+ wherein release would be indicated by a decrease in fluorescence upon
precipitation of the hydrophobic dye with its release into the aqueous media. The
choice of the zinc salt for the titration solution preparation became quite important
in this case.

In aqueous solutions of ZnCl2, insoluble precipitates of zinc

compounds are formed, lowering the Zn2+ concentration. Also, aqueous ZnCl2
solutions are more acidic (pH ~2) than those formed from other zinc salts. 0.5 and
0.1 M solutions of zinc acetate in MilliQ water were found to have a pH of ~7, which
was more desirable for our uses.

Initial fluorescence studies were completed with liposome solutions of 0, 10, and
20% ZnR1 with PC, hydrated in milliQ water. In each case, 100μL of liposome
solution was added to a 50μL well microcuvette. An initial fluorescence reading
was taken from 560 – 700 nm with excitation wavelength of 552 nm and the
liposome solution was then titrated with a 0.1 M aqueous solution of Zn(OAc)2 to
a total zinc concentration of 10 mM.

No significant release over the control

liposomes (0% ZnR1) was seen for either the 10 or 20% ZnR1 liposomes. Dilution
studies were also conducted where 50 μL of the given liposome solution was
diluted to a final volume of 3 mL with MilliQ water giving a lipid concentration of
0.033 mM. Again, titration from 0 to 10 mM Zn(OAc)2 resulted in no significant
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release of dye in any case.

Problems with release were attributed to the

electronegativity of the neighboring carbonyl groups, drawing electron density from
the TPA nitrogens.

A more electron poor TPA molecule would result in a

dampened chelation ability and thus hamper release. To combat this, other lipid
skeletons were designed, as will be described in the next sections.

2.6. Design and Synthesis of Zinc-Responsive Lipids of ZnR2
Type
Lipids of type ZnR2 were designed with differing tail connections. In contrast to
the electron withdrawing amide tails of ZnR1, these lipids exhibit a variety of bond
types (Figure 13). The zinc chelating core is the same, with these lipids being
based on TPA as well. The synthesis of these lipids proceeds through a common
intermediate, lending the quick accumulation of target compounds via these
methods.
2.6.1. Synthesis of ZnR2 Type Lipids
Synthesis of lipid ZnR2.1 (Figure 14) began with the formation of common
intermediate Z2.1. This is a core-first approach similar to that utilized to synthesize
lipid analog ZnR1.

Beginning with commercially available 5-bromo-2-

pyridinecarboxaldehyde, the TPA core was constructed by sequential reductive
aminations forming primary and secondary amine intermediates in situ, giving
intermediate Z2.1 at a 96% yield.87 Toward ZnR2.1, the bromine functionality was
utilized to perform a Sonogoshira coupling with 1-dodecyne. Despite varying
conditions, full conversion of all three bromide substitutions to alkyne tails was not
achieved in any appreciable yield, though product was detected by mass
spectroscopy. Other avenues were explored to increase conversion. Rather than
beginning with the fully constructed TPA core, individual pyridine-alkyne tail units
were synthesized (Figure 14). This synthesis began with the same 5-bromo-2pyridinecarboxaldehyde starting material that was utilized to form intermediate
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Figure 13. Structures of lipid targets ZnR2.1 – ZnR2.5.
These lipids stem from a common TPA core intermediate. Tails of varying
saturation and rigidity are designed to test the dependency of release on the
structure of the lipid tails.
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Figure 14. Synthetic steps toward ZnR2.1
i) NH4OAc, NaBH(OAc)3, dry DCM ii) 1-dodecyne, PdCl2(PPh3)2, CuI, 5:1
DMF:TEA iii) Z2.2, NaBH(OAc)3, dry DCM iv) 1) Z2.2, TEA, toluene, Dean Stark
trap, 100°C 2) NaBH4
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Z2.1. It was coupled successfully with 1-dodecyne in a palladium catalyzed cross
coupling reaction to yield intermediate Z2.2.

One pot reductive amination

conditions toward formation of the TPA core gave primary amine Z2.3 as the sole
product. Attempts to perform stepwise reductive aminations were also unable to
proceed past the primary amine intermediate. Tested conditions depicted in Figure
14 include the reaction of aldehyde Z2.2 with primary amine Z2.3 with sodium
trisacetoxyborohydride as the reducing agent, which gave only recovery of starting
materials and none of the desired product, ZnR2.1. Stepwise reductive aminations
with sodium borohydride as the reducing agent were also attempted, but only the
starting primary amine Z2.3 and the reduced version of aldehyde Z2.4, where the
aldehyde was reduced to a primary alcohol, were recovered in any case. The
amphiphilic nature of the starting materials may cause solubility issues hampering
the desired reactions. It was due to the hinderance of these steps that other lipid
targets were also pursued.

Lipid ZnR2.2 was targeted next. Common intermediate Z2.1 was coupled with
boronic acid precursor trans-octenylboronic acid via a palladium catalyzed SuzukiMiyaura coupling reaction, modified from the similar reaction scheme of Bravin et
al to suit these specific synthetic needs.87 The successful coupling gave lipid
ZnR2.2 at 34% yield (Figure 15). Based upon this success, other boronic acid
derivatives can be utilized for the Suzuki-Miyaura coupling step to target TPA core
lipids ZnR22.3-ZnR2.5.
2.6.2. Liposomal Studies with ZnR2 Type Lipids
With the completion and characterization of ZnR2.2, it was immediately utilized for
liposomal studies. Lipid ZnR2.2 was prepared at a 10 mM stock in chloroform and
liposomes were formed by the same techniques from section 2.5.3. Liposomes of
0, 10, and 20% ZnR2.2 hydrated with MilliQ water were prepared at 2 mM and
0.033 mM dilute liposome samples, as previously described.

Titration with

aqueous Zn(OAc)2 provided no release in any case, leading to a reevaluation of
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Figure 15. Synthesis of ZnR2.2
Conditions: i) trans-octenylboronic acid, Pd(PPh3)4, K2CO3, DMF/toluene/H2O
100°C
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the proposed release method. The draw of TPA was its selectivity for zinc over
other divalent metal ions. This selectivity is attributed to the small binding pocket
of the TPA core as compared to TPEN along with a more desirable pKa.79 This
could be negatively impacting the conformational change aspect of this platform.
The TPA unit would idealy be presented at the aqueous interface of the liposome
surface where, based on hydrophilicity, the nitrogens of the pyridine rings along
with the central tertiary nitrogen could be oriented upward, essentially preforming
a binding pocket for zinc to fall in to (Figure 16). If this is the case, there would not
be a large conformational change between bound and unbound states of the
switch. This would explain the failure of both ZnR1 and ZnR2.2. There also exists
a pH dependency of these lipid analogs. At low pH, 6.2 or below, a large portion
of TPA becomes protonated.79 As modeled in Figure 16, protonation of the central
nitrogen of TPA will facilitate the preformation of the proposed zinc binding pocket,
further dampening the conformational change aspect of these TPA based lipid
analogs.

To determine if the lipids were capable of chelating zinc and to rule out a lack of
binding as the reason for lack of release, UV-Vis studies were performed.
Solutions of 40 μM of lipids ZnR1 and ZnR2.2 were prepared in pH 7.45 PIPES
buffer. An initial scan of UV-Vis absorbance was taken. Then, a sample that was
40 μM in lipid and 200 μM in ZnCl2 was prepared and UV-Vis spectra were
collected at time 0, 10, and 20 minutes. ZnR1 did not exhibit a specific pattern in
changes, further strengthening the previous assertion that its more electron
withdrawn TPA core will not bind zinc strongly. However, ZnR2.2 showed a steady
decrease in absorbance at ~283 nm. This can be attributed to the chelation of zinc
decreasing the absorption of the TPA core.79 This indicates that lipid ZnR2.2 is
capable of chelating zinc, adding more weight to the argument that the
presentation of TPA at the surface is preformed in an ideal conformation for the
acceptance of zinc.

Taking these results into consideration, a shift was made in
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Figure 16. Optimal presentation of TPA core at the aqueous interface of the
liposomal membrane
All nitrogen units will be oriented upward to the aqueous interface, preforming a
binding pocket for incoming Zn2+ ions (structure a). This may not lead to a large
conformational change of the core upon chelation (structure b), thus dampening
release. Protonation of the central TPA nitrogen may also lead to preorganization of the pyridal units (structure c) strengthening the preformed binding
pocket for zinc.
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synthetic efforts to also target a different zinc chelator as the lipid core, as will be
expanded on in the next section.

To further investigate the pH dependence of the binding ability of ZnR2.2,
liposomes composed of 0, 25, 50 and 75% ZnR2.2 with PC were prepared in pH
7 PIPES buffer. Though the same thin film hydration and extrusion methods were
followed as before, no fluorescence, by extension no encapsulated nile red
lipophilic dye, was detected via fluorimetry experiments for any of the liposome
formulations in either concentrated or dilute liposome samples. This led to the
determination that PIPES buffer will not be suitable for liposome studies. Next,
tris-buffered saline (TBS) at pH 8 was used to hydrate the lipid films. Liposomes
of 0, 25, 50, 75, and 95% ZnR2.2 were formed at 2 mM lipid content as previously
described and 100 μL of the liposome solution was titrated with aqueous 0.1 M
Zn(OAc)2 to a total concentration of 10 mM Zn2+. Under these conditions, an
increase in release was seen for the liposomes composed of 50% or more of lipid
switch with PC when compared to control liposomes (Figure 17). While the release
was not extensive, at only 13, 17, and 29% release for 50, 75, and 95% ZnR2.2,
respectively with background release at 9% in absence of trigger lipid, these
results indicated that lipid ZnR2.2 is able to induce membrane destabilization in
the presence of increased concentrations of zinc ions. These preliminary results
are indicative that pH control of the liposomal solution is important to the chelation
ability of the TPA based lipid switches. From here, further changes to the liposome
composition were studied to see the effects on dye release properties.

Phosphatidyl ethanolamine (PE) is a non membrane forming lipid, however, when
mixed with other lipids it can form stable membranes. For the following studies,
the incorporation of ZnR2.2 was held constant at 50% while the amounts of PE
and PC were varied. PE was incorporated at 10, 25, and 50% with the remaining
percentage being made up of PC. The lipid films were formed by the same protocol
as the previous studies and hydrated with TBS. Of the given preparations, that
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composed of 50% PE and 50% ZnR2.2 did not form liposomes. Titration data for
the other liposome preparations is given in Figure 17.

It was seen that

incorporation of 25% PE was optimal for release with 41 % release seen for these
liposomes. This was a large increase over liposomes containing 50% synthetic
lipid in the absence of PE which saw only 13% release. It is assumed that the
incorporation of PE predisposed the liposomes fusion and membrane disruption,
making the small hypothesized conformational change previously postulated in
Figure 16 a large enough factor to effect appreciable release. Still, a more effective
conformational lipid switch was desired, so other lipid analogs were designed as
will be discussed in the next section.
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Figure 17. Dye release profile of lipid switch ZnR2.2
TOP: Liposomes composed of PC and lipid analog ZnR2.2. Appreciable release
was only seen at high percentages of ZnR2.2 where liposomes of 95% ZnR2.2
gave 29% release. BOTTOM: Incorporation of PE into the liposomal formulations
decreased the required synthetic lipid content while increasing dye release.
Liposomes of 25% PC, 25% PE, 50% ZnR2.2 gave 41% release.
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2.7.

Design and Synthesis of Zinc-Responsive Lipids of ZnR3

Type
With the limited release of the TPA based lipid switches, TPEN was next targeted
as a lipid core ion chelator. It was hypothesized that due to the presentation of
TPA at the surface of the liposomal membrane, there may not be a significant
conformational change with chelation of zinc. The use of TPEN, however, could
change that as it was envisaged that TPEN based lipids, when inserted into the
membrane, would have greater separation between the pyridal units of the
chelating core than those in the TPA based lipid analogs. Upon treatment with
zinc, it is hypothesized that these units would have to come in closer proximity in
order to properly chelate an ion (Figure 18). This should cause a large enough
conformational change in the lipid skeleton to disturb the membrane thus causing
release of cargo. As previously described, TPEN has a higher affinity for zinc (0.3
fM) as compared to TPA (10 pM) though it is less selective among other divalent
metal cations.79 This is also advantageous as the increased affinity will potentiate
greater chelation ability. These structural and affinity differences will be beneficial
to our goal of designing an effective lipid switch. Similar chemistry to that used to
synthesize lipid ZnR2.2 will be utilized to form the TPEN core and attach a variety
of alkyl tails to quickly and efficiently build a number of lipid skeletons. The
targeted TPEN based lipids are shown in Figure 18.
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a)

b)

Figure 18. TPEN chelation of zinc and structures of lipid analogs ZnR3.1 –
ZnR3.4
a) A greater potential for conformational change and membrane disruption is
hypothesized for TPEN based lipid switches as compared to TPA based lipid
switches. R= alkyl tail. b) Target structures of TPEN lipid analogs designed
similarly to ZnR2 type lipids. These lipids are based on a common TPEN zinc
chelating core with a variety of possible alkyl tails.
49

2.7.1. Synthesis of ZnR3 Type Lipids
The synthesis of the TPEN core was pursued by multiple routes (Figure 19). The
first route to the TPEN core began with the reduction of common starting material
5-bromo-2-pyridinecarboxaldehyde to transform the aldehyde functionality to an
alcohol, Z3.1. This alcohol intermediate was then chlorinated to give intermediate
Z3.2. Coupling of chloride Z3.2 with ethylenediamine was attempted with various
basic conditions including NaOH90 and K2CO3, neither of which successfully
yielded the target TPEN unit Z3.3. Another route to intermediate Z3.3 included the
stepwise formation of secondary amine Z3.4 through successive reductive
aminations with ammonium acetate as the nitrogen source and sodium
borohydride as the reducer. However, the initial primary amine was not recovered.
A one pot reductive amination was also pursued utilizing a weaker hydride reducer
in sodium triacetoxyborohydride which yielded tertiary amine Z2.1 as the main
product rather than the desired secondary amine Z3.4. The next plausible route
that was designed was to synthesize primary amine Z3.7 through an azide
reduction and then couple that amine with the readily available aldehyde precursor
through a reductive amination to give secondary amine Z3.4. This synthetic route
began with alcohol intermediate Z3.1, synthesized as before, which was then
activated by transformation into tosylate Z3.5. Substitution of the tosylate with
sodium azide was successful in installing the required nitrogen unit. The azide can
then be reduced via palladium catalyzed hydrogenation to give primary amine
Z3.7.

This will then be coupled with the readily available aldehyde to give

secondary amine Z3.4. To construct the TPEN core, intermediate Z3.4 will be
coupled with dibromoethane in a double substitution reaction to give common
intermediate Z3.3. When the TEPN core intermediate is successfully synthesized
it will be coupled with the desired boronic acid alkyl tail precursor to yield the target
lipid analogs, ZnR3.1 – ZnR3.4. Lipid analog ZnR3.1 will be targeted first as it is
analogous to ZnR2.2 which performed well in the TPA based studies. Facile
switching of boronic acid functionality will provide quick access to the rest of the
.
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Figure 19. Synthetic routes toward TPEN based lipid analogs
Various synthetic routes to synthetic intermediate Z3.3 and lipid analog ZnR3.1. Conditions: i) NaBH4, EtOH, 0°C ii)
SOCl2, toluene iii) ethylenediamine, NaOH(aq), DCM90 iv) ethylenediamine, K2CO3, MeCN v) NH4OAc, NaBH(OAc)3,
DCM vi) 1) NH4OAc, DCM, NaBH4 2) 5-bromo-2-pyridinecarboxaldehyde, DCM, NaBH4 vii) 1,2-dibromoethane, K2CO3,
MeCN viii) DMAP, TEA, pTsCl, DCM ix) NaN3, DMF x) 10% Pd/C, H2 xi) 5-bromo-2-pyridinecarboxaldehyde, EtOH,
NaBH4 xii) 1,2-dibromoethane, K2CO3, MeCN xiii) trans-octenylboronic acid, Pd(PPh3)4, K2CO3, DMF/toluene/H2O
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target lipid skeletons. As these targets are successfully synthesized, they will be
applied in liposomal release studies to determine their release characteristics.

Upon completion of synthesis of the TPEN based lipid analogs the optimized dye
release conditions as determined in the TPA based studies of section 2.6.2 will be
applied with formation of 200 nm liposomes composed of trigger lipid, PC, and/or
PE in TBS. The difference in pKa of TPEN as compared to TPA may influence the
release profile and binding ability of the second set of analogs (ZnR3 type), so
determination of the optimal conditions for each lipid type may be required. Taking
all of the experimental optimization into account, the TPEN lipid switches are
hypothesized to have a greater potential for release than their smaller TPA
counterparts due to their higher propensity for conformational change upon ion
chelation. The exact release profiles will be determined upon successful synthesis
of each analog

2.8. Summary and Future Work
Molecular recognition as stimuli for the release of payload from a therapeutic
liposome represents a new level of targeted therapeutics. The ability to harness
a unique physiological aspect of a disease for treatment allows for less off target
interactions and a more concise treatment. Toward this end, this work proposed
a number of synthetic lipid switches for the recognition of zinc. Based on wellknown zinc chelators, TPA and TPEN, it was envisioned that upon recognition of
zinc there would be a conformational change within the lipid causing it to become
a non-bilayer lipid. This would ideally destabilize the membrane and potentiate
cargo release.

Currently, of the available completed lipid switches only ZnR2.2 causes cargo
release. This required a significant amount of synthetic lipid which has been
attributed to the way in which the TPA based lipids present themselves at the
bilayer aqueous interface. It is hypothesized that the chelating nitrogens are
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presented in such a way that they readily bind with zinc without having to rotate
within the membrane. This setback was countered with the design of TPEN
based lipid switches which have the potential for a greater conformational
change upon chelation of zinc. Future work with this research will include
completion of the synthesis of compounds ZnR2.3-ZnR2.5 and further liposomal
studies of these lipid switches along with the completed lipid ZnR2.2.
Furthermore, the completion of the synthesis of the panel of TPEN lipids ZnR3.1Znr3.4 will provide a large panel of lipid switches for study of their cargo release
profiles. Taken together, these lipid conformational switches will provide new
insights into the possibilities of triggered liposomal release.

2.9. Synthetic Details and Compound Characterization
2.9.1. General Experimental Information
Reagents and solvents were generally purchased from Acros, Aldrich, or Fisher
Scientific and used without further purification. PC (ʟ-α-phosphatidylcholine, mixed
isomers from chicken eggs) was purchased from Avanti Polar Lipids, Inc. Dry
solvents were obtained from a Pure solvent delivery system purchased from
Innovative Technology, Inc. Column chromatography was performed using 230300 mesh silica gel purchased from Sorbent Technologies. NMR spectra were
obtained using Varian Mercury Vx 300 MHz and Varian 500 MHz spectrometers.
Mass spectra were obtained with JEOL DART-AccuTOF and Q-Star XL
quadrupole time-of-flight hybrid mass spectrometers (Applied Biosystems, Foster
City, CA). Liposome extruder and polycarbonate membranes were obtained from
Avestin (Ottawa, Canada). Ultrapure water was purified via a Millipore water
system. Fluorescence studies were performed using a Cary Eclipse Fluorescence
Spectrophotometer.
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2.9.2. Synthetic Details: Z1 Compounds

Diethylpyridine-2,4-dicarboxylate (Z1.1)85
Commercially available 2,4-pyridine dicarboxylic acid (150.0 mg, 0.90 mmol, 1.0
equiv) and para-toluenesolufonic acid (pTsOH, 342.6 mg, 1.80 mmol, 2.4 equiv)
were dissolved in 15 mL EtOH and refluxed for 24 h. The reaction mixture was
then subjected to rotary evaporation to remove the solvent. The residue was
dissolved in 15 mL of CHCl3 and washed with saturated NaHCO3 (15 mL). The
aqueous layer was extracted with 3 x 15 mL CHCl3. The organics were combined,
dried with MgSO4, filtered, and the solvent was removed by rotary evaporation.
Compound Z1.1 was obtained as a clear oil/ white solid (190.3 mg, 95% yield). 1H
NMR (300 MHz, CDCl3): δ 0.96 (m, 6H), 3.99 (m, 4H), 7.53 (d, 1H, J = 5.29 Hz),
8.07 (s, 1H), 8.41 (d, 1H, J = 4.77 Hz) 13C NMR (125 MHz, CDCl3): δ 14.17, 14.29,
62.31, 62.3, 124.32, 126.02, 139.19, 149.14, 150.55, 164.23, 164.45. Molecular
formula: C12H14O4. DART-AccuTOF-Mass Spec: [M+1] predicted: 224.09173
[M+1] found: 224.08598

Ethyl 2-formylisonicotinate (Z1.2)86
Compound Z1.1 (597.5 mg, 2.69 mmol, 1.0 equiv) was dissolved in 20 mL dry THF
under stirring and nitrogen atmosphere and then cooled to -78°C in a dry ice/
acetone bath. DIBAL-H (10.7 mL of a 1 M solution in hexane, 10.75 mmol, 4.0
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equiv) was added dropwise to the cold, stirring solution. The reaction was stirred
for 2.5 h at -78°C and then poured over ice cold acetic acid:deionized water (2
mL:10 mL) and stirred for 1 h. The pH of the solution was next brought to ~8 by
adding saturated NaHCO3. The resulting solution was extracted with 3 x 15 mL
EtOAc and the organic layers were combined, washed with 20 mL saturated
NaHCO3, dried with MgSO4, filtered, and the solvent was removed by rotary
evaporation. The crude reaction mixture was purified via column chromatography
with 10-25-50% EtOAc in hexane to provide Z1.2 as a white solid. (300.8 mg, 65%
yield). 1H NMR (300 MHz, CDCl3): δ 1.39 (t, 3H, J = 7.20), 4.41 (q, 2H, J = 7.22
Hz), 8.05 (dd, 1H, J = 4.96 Hz, 1.67 Hz), 8.43 (s, 1H), 8.91 (dd, 1H, J = 4.87 Hz,
0.81 Hz), 10.10 (s,1H)

13C

NMR (75 MHz, CDCl3): δ 14.13, 62.23, 120.84, 126.84,

139.12, 150.95, 153.62, 164.10, 192.52. Molecular formula: C10H10O3. DARTAccuTOF-Mass Spec: [M+1] predicted: 180.06552 [M+1] found: 180.09109

Triethyl 2,2',2''-(nitrilotris(methylene))triisonicotinate (Z1.3)87
Compound Z1.2 (301.0 mg, 1.70 mmol, 3.0 equiv) and NH4OAc (43.2 mg, 0.48
mmol, 1.0 equiv) were dissolved in 7 mL dry DCM and the reaction was stirred
under N2 for 1 h. NaBH(OAc)3 was added in 3 portions (120.1 mg, 0.57 mmol, 1.0
equiv per addition) and the reaction was stirred for 1 h in between each addition.
After the final hydride addition, the reaction was allowed to stir overnight at rt under
N2. The solvent was removed under reduced pressure and the reaction residue
was dissolved in 15 mL EtOAc and washed with 15 mL of 0.1 M KOH. The organic
layer was dried with MgSO4, filtered, and the solvent removed under reduced
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pressure. Column chromatography with 0-10% MeOH:CHCl3 gave 140.5 mg of
the product as a clear oil (49% yield). 1H NMR (300 MHz, CDCl3): δ 1.40 (t, 9H, J
= 6.66 Hz), 4.03 (s, 6H), 4.41 (q, 6H, J = 7.23 Hz), 7.69 (dd, 3H, J = 5.10 Hz, 1.51
Hz), 8.07 (s, 3H), 8.67 (dd, 3H, J = 5.05 Hz, 0.73 Hz)

13C

NMR (75 MHz, CDCl3):

δ 14.15, 60.04, 61.69, 121.25, 122.40, 138.25, 149.85, 160.14, 165.18 Molecular
formula: C27H30N4O6. Q-Star XL quadrupole TOF-Mass Spec: [M+1] predicted:
507.22381 [M+1] found: 507.2337

2,2',2''-(Nitrilotris(methylene))tris(N-dodecylisonicotinamide) (ZnR1)88
Dodecylamine (82.3 mg, 0.44 mmol, 18.0 equiv) was dissolved in 1 mL dry THF
and the mixture was cooled to 0°C under N2. DIBAL-H (422 μL of a 1 M in hexane
solution, 0.42 mmol, 17.1 equiv) was added to the cooled solution and the mixture
was stirred for 2 h while warming to rt. Triester Z1.3 (12.5 mg, 0.02 mmol, 1equiv)
was dissolved in 0.5 mL THF with stirring under N2. The previous activated amine
solution was added dropwise to triester solution via cannula. The reaction was
then brought to 50°C and stirred overnight under N2. The reaction was then cooled
to 0°C and quenched with 1 mL of 0.5 M KHSO4. The reaction mixture was then
extracted with 5mL DCM and the resulting aqueous layer was then extracted with
5mL of CHCl3. The combined organic layers were washed with 10 mL saturated
NaCl, dried with MgSO4, filtered, and dried via rotary evaporation.

Column

chromatography with 0-60% EtOAc:hexane followed by 10% MeOH:CHCl3 gave
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ZnR1 as a yellow oil (3.1 mg, 17% yield). 1H NMR (300 MHz, CDCl3): δ 0.71 (t,
9H, J = 7.07 Hz), 1.10 (s, 54H), 1.49 (m, 6H), 3.25 (m, 6H), 3.88 (s, 6H), 7.47 (d,
3H, J = 4.38 Hz), 7.79 (s, 3H), 8.23 (bs, 3H), 8.41 (d, 3H, J = 4.97 Hz) Molecular
formula: C57H93N7O3. Q-Star XL quadrupole TOF-Mass Spec: [M+Na] predicted:
946.72321 [M+Na] found: 946.7208

Ethyl 2-(hydroxymethyl)isonicotinate (Z1.4)85
Compound Z1.1 (636.0 mg, 2.86 mmol, 1.0 equiv) was dissolved in 10 mL dry,
degassed EtOH. The solution was cooled below 0°C in an ice/salt bath with
stirring. NaBH4 (64.7 mg, 1.71 mmol, 0.6 equiv) was added in small portions to
the cooled solution to maintain temperature of -10 to 0°C. Then, freshly crushed
anhydrous CaCl2 (310.7 mg, 2.86 mmol, 1.0 equiv) was slowly added to the cold
reaction. The reaction was allowed to stir for 3 h at 0°C under N2 after addition of
all reagents. After 3 h of reacting, the pH of the solution was adjusted to 6 with 1
N HCl. Next the solution was filtered to remove solid salts and condensed under
reduced pressure.

Column chromatography with 10-100% EtOAc:hexanes

yielded Z1.4 as a white solid (344.6 mg, 68% yield). 1H NMR (500 MHz, CDCl3):
δ 1.41 (t, 3H, J = 7.54 Hz), 3.57, (bs, 1H), 4.41, (q, 2H, J = 7.24 Hz), 4.83, (s, 2H),
7.76 (d, 1H, J = 4.92 Hz), 7.82 (s, 1H), 8.69 (d, 1H, J = 4.99 Hz)

13C

NMR (125

MHz, CDCl3): δ 14.18, 61.88, 64.20, 119.75, 121.58, 138.40, 149.30, 160.20,
164.96

Molecular formula: C10H12O3. DART-AccuTOF-Mass Spec: [M+1]

predicted: 182.08117 [M+1] found:182.21761
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Ethyl 2-(bromomethyl)isonicotinate (Z1.5)
Compound Z1.4 (181.2 mg, 1.01 mmol, 1.0 equiv) was dissolved in 4mL dry DCM.
PBr3 (1.4 mL, 14.89 mmol, 14.74 equiv) was added and the reaction was stirred
for 6 h at rt under nitrogen. Next, the reaction was cooled in an ice bath and 1.5
mL methanol was added dropwise to quench any excess PBr3. The reaction
mixture was washed three times with water, dried with MgSO4, and the solvent
was removed via rotary evaporation without the application of heat. Column
chromatography with 10-25% EtOAc:hexane yielded Z1.5 as a clear oil (60.2 mg,
quant). Compound Z1.5 was found to quickly decompose to a purple oil unless
stored at -80°C. 1H NMR (300 MHz, CDCl3): δ 1.41 (t, 3H, J = 7.09 Hz), 4.41 (q,
2H, J = 7.16 Hz), 4.60 (s, 2H), 7.76 (d, 1H, J = 4.49 Hz), 7.98 (s, 1H), 8.72 (s, 1H)
13C

NMR (75 MHz, CDCl3): δ 14.19, 33.18, 61.98, 109.99, 122.24, 138.89, 150.44,

157.90, 164.62. Molecular formula: C10H11BrO2. DART-AccuTOF-Mass Spec:
[M+1] predicted: 243.99677, 245.99472 [M+1] found: 243.99381, 245.98980

Ethyl 2-((tosyloxy)methyl)isonicotinate (Z1.6)
Compound Z1.4 (20.0 mg, 0.11 mmol, 1.0 equiv), DMAP (2.4 mg, 0.02 mmol, 0.2
equiv), and TEA (16.5 μL, 0.22 mmol, 2.0 equiv) were dissolved in 5 mL dry DCM.
pTsCl (41.9 mg, 0.22 mmol, 2.0 equiv) was added and the reaction was stirred
overnight under N2. Next, the reaction was diluted with 5 mL DCM and washed
twice with 10 mL 1 N HCl. The aqueous layer was extracted with 3 x 10 mL DCM.
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The organic layers were combined, dried with MgSO4, filtered, and the solvent was
removed by rotary evaporation. Purification via column chromatography with 1075% EtOAc:hexane gave compound Z1.6 as a white solid (17.9 mg, 49% yield).
1H

NMR (300 MHz, CDCl3): δ 1.42 (t, 3H, J = 7.16 Hz), 2.44 (s,3H), 4.42 (q, 2H, J

= 7.20 Hz), 5.19 (s, 2H), 7.34 (d, 2H, J = 8.11 Hz), 7.78 (dd, 1H, J = 5.08 Hz, 1.58
Hz), 7.84 (td, 2H, J = 8.39 Hz, 1.99 Hz), 7.92 (s, 1H), 8.66 (d, 1H, J = 4.91 Hz)

13C

NMR (125 MHz, CDCl3): δ 14.19, 21.63, 62.09, 70.99, 121.30, 122.76, 128.10,
129.95, 132.54, 139.13, 145.19, 149.75, 154.69, 164.42 Molecular formula:
C17H18O5S.

Ethyl 2-(azidomethyl)isonicotinate (Z1.7)
Compound Z1.5 (30.5 mg, 0.13 mmol, 1.0 equiv) and NaN3 (24.4 mg, 0.38 mmol,
3 equiv) were dissolved in 5 mL of dry DMF. The reaction was then heated to 85°C
and allowed to stir overnight. Next the reaction was diluted with 20 mL of EtOAc
and the solvent was removed via rotary evaporation. The reaction residue was
dissolved in 10 mL EtOAc and washed with 10 mL water. The aqueous layer was
then extracted with 3 x 7 mL EtOAc. The combined organic layers were washed
with 5 x 10 mL ice cold water, 1 x 20 mL saturated NaCl, and then dried with
MgSO4. Then the reaction was filtered and the solvent was removed via rotary
evaporation. The target compound was obtained in a quantitative yield as a yellow
oil (25.8 mg).

The same reaction conditions applied to Z1.6 also gave a

quantitative transformation to Z1.7. 1H NMR (300 MHz, CDCl3): δ 1.42 (t, 3H, J =
7.04 Hz), 4.43, (q, 2H, J = 7.11 Hz), 4.57, (s, 2H), 7.81 (dd, 1H, J = 5.03 Hz, 1.44
Hz), 7.90 (s, 1H), 8.75 (dd, 1H, J = 5.02 Hz, 0.74 Hz).

13C

NMR (125 MHz, CDCl3):

δ 14.18, 55.42, 61.96, 121.15, 121.16, 138.78, 150.43, 156.91, 164.78. Molecular
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formula: C10H11N3O2. DART-AccuTOF-Mass Spec: [M+1] predicted: 207.08765
[M+1] found: 207.09040

Ethyl 2-(aminomethyl)isonicotinate (Z1.8)
Compound Z1.7 (12.3 mg, 0.06 mmol, 1.0 equiv) was dissolved in 5 mL of EtOAc.
10% Pd/C (2.5 mg, 20% wt of azide, 0.002 mmol Pd) was added to the reaction
flask and the atmosphere was replaced with H2. After 1 hour of stirring, the
atmosphere was replaced with N2 and a second addition of Pd/C (0.8 mg, 5% wt
of azide, 0.0008 mmol Pd) was added and the atmosphere replaced with H2. The
reaction was allowed to stir overnight under hydrogen atmosphere. Next, the
reaction was filtered through celite to remove the palladium catalyst and the
solvent was removed via rotary evaporation. The crude reaction mixture was
purified via column chromatography with 5-25% MeOH:CHCl3 and compound Z1.8
was collected as a yellow oil (4.7 mg, 40% yield). The product gave a yellow spot
by ninhydrin stain on TLC. 1H NMR (500 MHz, MeOD): δ 1.40 (t, 3H, J = 7.09 Hz),
4.10 (bs, 2H), 4.42 (q, 2H, J = 7.19 Hz), 7.82 (d, 1H, J = 4.48 Hz), 7.96 (s, 1H),
8.71 (d, 1H, J = 4.65 Hz). Molecular formula: C10H13NO2. DART-AccuTOF-Mass
Spec: [M+1] predicted: 181.09715 [M+1] found: 181.10196

2-(Hydroxymethyl)isonicotinic acid (Z1.10)
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Compound Z1.4 (15.6 mg, 0.09 mmol, 1.0 equiv) was dissolved in 6 mL THF:H2O
(1:1 v/v). Freshly ground KOH (14.5 mg, 0.26 mmol, 3.0 equiv) was added to the
stirring reaction. Next, the reaction mixture was heated at reflux (100°C) for 20 h.
The reaction was then allowed to cool to rt and then further cooled in an ice bath.
The pH of the solution was adjusted to ~4-5 with 3 N HNO3. The solvent was then
removed via rotary evaporation. The solid residue remaining in the flask was
washed with 3 x 10 mL portions of EtOH. The ethanol washes were transferred to
a clean flask and the solvent was removed under reduced pressure. The resulting
residue was dissolved in hot isopropanol and filtered. Removal of solvent under
reduced pressure gave compound Z1.10 as a white solid (12.2 mg, 93% yield). 1H
NMR (300 MHz, CDCl3/MeOD): δ 4.59 (s, 2H), 7.57 (dd, 1H, J = 5.20 Hz, 1.50
Hz), 7.80 (s, 1H), 8.37 (d, 1H, J = 5.26 Hz). Molecuar formula: C8H8O3. DARTAccuTOF-Mass Spec: [M+1] predicted: 154.04987 [M+1] found: 154.04561
2.9.3. Synthetic Details: Z2 Compounds

Tris((5-bromopyridin-2-yl)methyl)amine (Z2.1)87
5-Bromo-2-pyridinecarboxaldehyde (1.50 g, 8.06 mmol, 3.0 equiv) and NH4OAc
(207.2 mg, 2.69 mmol, 1 equiv) were dissolved in 25 mL of dry DCM and stirred
for 1 hour. 3 equivalents of NaBH(OAc)3 were added in 1 equiv portions ( 565.2
mg, 2.69 mmol, per addition) with 1 h of stirring between each addition. The
reaction was left to stir overnight and then the solvent was removed under
vacuum, and the residue was dissolved in 30 mL EtOAc. The reaction was washed
with 20 mL 0.1 M KOH three times, dried with MgSO4, filtered, and the solvent
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removed by rotary evaporation. Recrystallization twice from 50:50 THF:hexane
and rinsing with cold hexane gave the product as a white needlelike solid (1.35 g,
96% yield). 1H NMR (300 MHz, CDCl3): δ 3.81 (s, 6H), 7.40 (d, 3H, J = 8.36 Hz),
7.76 (dd, 3H, J = 8.22 Hz, 2.25 Hz), 8.59 (d, 3H, J = 2.31 Hz) 13C NMR (75 MHz,
CDCl3): δ 59.26, 119.17, 124.44, 139.05, 150.22, 157.40. Molecular formula:
C18H15Br3N4.

DART-AccuTOF-Mass Spec: [M+1] predicted: 526.88991,

528.88787 [M+1] found: 526.91788, 528.83407

Tris((5-((E)-oct-1-en-1-yl)pyridin-2-yl)methyl)amine (ZnR2.2)87
Compound Z2.1 (25.0 mg, 0.05 mmol, 1.0 equiv), trans-octenylboronic acid (44.0
mg, 0.28 mmol, 6.0 equiv), and K2CO3 (45.5 mg, 0.33 mmol, 7.0 equiv) were
dissolved in a 4:2:1 mixture of DMF:toluene:deionized water under Ar. Pd(PPh 3)4
(3.8 mg, 7 mol%) was added and the atmosphere of the reaction vessel was
evacuated and replaced with Ar three times. Next, the reaction was heated at
100°C for 48 h, followed by removal of the solvent by rotary evaporation. The
reaction residue was dissolved in 15 mL EtOAc and was washed with 3 x 15 mL
water. The organic layer was dried with MgSO4, filtered, and the solvent was
removed by rotary evaporation.

Column chromatography with 0-10%

MeOH:CHCl3 gave the product as a yellow oil (9.9 mg, 34% yield). 1H NMR (300
MHz, CDCl3): δ 0.89 (t, 9H, J = 6.79 Hz), 1.30 (s, 18H), 1.45 (quint, 6H, J = 7.26),
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2.21 (q, 4H, J = 6.80 Hz), 3.83 (s, 6H), 6.28 (m, 6H), 7.46 (d, 3H, J = 8.09 Hz),
7.62 (dd, 3H, J = 8.04 Hz, 2.28 Hz), 8.45 (d, 3H, J = 1.80 Hz) 13C NMR (75 MHz,
CDCl3): δ 14.07, 22.59, 28.87, 29.14, 31.69, 33.13, 59.58, 122.86, 126.00, 131.95,
132.89, 133.27, 147.07. Molecular formula: C42H60N4. DART-AccuTOF-Mass
Spec: [M+1] predicted: 621.48907 [M+1] found: 621.43042

5-(Dodec-1-yn-1-yl)picolinaldehyde (Z2.2)
5-Bromo-2-pyridinecarboxaldehyde (50.0 mg, 0.27 mmol, 1.0 equiv), 1-dodecyne
(36.3 μL, 0.27 mmol, 1.0 equiv), CuI (0.5 mg, 0.003 mmol, 1 mol% of bromide),
and PdCl2(PPh3)2 (5.7 mg, 0.008 mmol, 3 mol% of bromide) were dissolved in 2
mL of a mixture of dry, degassed DMF:TEA (5:1). The reaction vessel was flushed
with N2 and stirred overnight at 65°C. The reaction was then cooled and diluted
with 15 mL of water. The mixture was extracted with 15 mL EtOAc and the organic
layer was washed twice with 10 mL water, once with 10 mL saturated NaCl, was
dried with MgSO4, filtered, and the solvent was removed under reduced pressure.
Purification via column chromatography with 0-2% EtOAc:hexane yielded Z2.2 as
a yellow oil (40.3 mg, 55% yield).

1H

NMR (300 MHz, CDCl3): δ 0.86 (t, 3H, J =

6.87 Hz), 1.26 (s, 12H), 1.44 (quint, 2H, J = 7.28 Hz), 1.62 (quint, 2H, J = 7.13 Hz),
2.45 (t, 3H, J = 6.99 Hz), 7.80 (dd, 1H, J = 8.16 Hz, 1.72 Hz), 7.87 (d, 1H, J = 8.02
Hz), 8.73 (s, 1H), 10.04 (s, 1H).

13C

NMR (75 MHz, CDCl3): δ 4.08, 19.61, 22.65,

28.33, 28.91, 29.08, 29.28, 29.48, 29.54, 31.95, 98.55, 120.88, 125.76, 139.25,
150.43, 152.55, 192.60. Molecular formula: C18H25NO. DART-AccuTOF-Mass
Spec: [M+1] predicted: 272.20089 [M+1] found: 272.08493
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(5-(Dodec-1-yn-1-yl)pyridin-2-yl)methanamine (Z2.3)87
Compound Z2.2 (21.7 mg, 0.08 mmol, 3.0 equiv) and NH4OAc (2.3 mg, 0.03 mmol,
1 equiv) were dissolved in 2 mL of dry DCM and stirred for 1 h. 3 equivalents of
NaBH(OAc)3 were added in 1 equivalent portions (6.4 mg, 0.03 mmol per addition)
with 1 hour of stirring between each addition. The reaction was left to stir overnight
and then the solvent was removed under vacuum, and the residue was dissolved
in 7 mL EtOAc. The reaction was washed with 7 mL 0.1 M KOH three times, dried
with MgSO4, filtered, and the solvent removed by rotary evaporation. Column
chromatography with 10-50% EtOAc:hexane gave Z2.3 as the major product
(though tertiary amine ZnR1 was the desired product) as a white solid (11.7 mg,
quant). 1H NMR (300 MHz, CDCl3): δ 0.88 (t, 3H, J = 6.81 Hz), 1.27 (s, 12H), 1.44
(m, 2H, J = 6.96 Hz), 1.61 (quint, 2H, J = 7.13 Hz), 2.42 (t, 2H, J = 6.99 Hz), 4.74
(s, 2H), 7.18 (d, 1H, J = 8.08 Hz), 7.67 (d, 1H, J = 8.38 Hz), 8.56 (s, 1H). Molecular
formula: C18H28N2.

2.9.4. Synthetic Details: Z3 Compounds
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5-bromo-2-pyridinecarboxaldehyde (1.0 g, 5.38 mmol, 1.0 equiv) was dissolved in
20 mL of EtOH and the solution was cooled to 0°C. NaBH4 (1.1 g, 28.22 mmol,
5.3 equiv) was added in small portions to the cooled solution to maintain a
temperature of 0°C and then the reaction was stirred for 4 h at rt. Next, the solvent
was removed via rotary evaporation and the resulting residue was dissolved in 20
mL of DCM and was washed three times with 20 mL of water. The organic layer
was then dried with MgSO4, filtered, and the solvent removed under rotary
evaporation. Z3.1 was recovered as a white solid without further purification (757.2
mg, 75% yield) 1H NMR (300 MHz, CDCl3): δ 3.14 (bs, 1H), 4.73 (s, 2H), 7.20 (d,
1H, J = 8.29 Hz), 7.82 (dd, 1H, J = 8.33 Hz, 2.31 Hz), 8.62 (d, 1H, 2.17 Hz)

13C

NMR (75 MHz, CDCl3): δ 63.88, 119.07, 121.76, 139.38, 149.59, 157.71
Molecular formula: C6H6BrNO

Z3.1 (757.2 mg, 4.03 mmol, 1.0 equiv) was dissolved in 20 mL of dry toluene.
SOCl2 (877.0 μL, 12.09 mmol, 3.0 equiv) was added dropwise to the solution of
alcohol Z3.1 in toluene and allowed to stir for 3 h at rt then quenched with 20 mL
of saturated NaHCO3, extracted three times with 20 mL of DCM, and the combined
organic fractions were dried with MgSO4, filtered, and the solvent was removed via
rotary evaporation. Column chromatography with 10-50% acetone:hexane gave
compound Z3.2 as a pale yellow oil (396.5 mg, 48% yield)

1H

NMR (300 MHz,

CDCl3): δ 4.57 (s, 2H), 7.31 (d, 1H, J = 8.38 Hz), 7.77 (dd, 1H, J = 8.33 Hz, 2.47
Hz), 8.56 (dd, 1H, J = 2.42 Hz, 0.57 Hz)

13C

NMR (75 MHz, CDCl3): δ 45.94,

120.08, 124.05, 139.56, 150.43, 155.08 Molecular formula: C6H5BrClN
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Z3.1 (565.4 mg, 3.00 mmol, 1.0 equiv), DMAP (73.5 mg, 0.60 mmol, 0.2 equiv),
and TEA (836.3 uL, 6.00 mmol, 2.0 equiv) were dissolved in 30 mL dry DCM then
pTsCl (1.1 g, 6.00 mmol, 2.0 equiv) was added and the reaction was stirred under
N2 overnight. Then, the reaction was transferred to a separatory funnel, washed
twice with 20 mL 1N HCl, and the aqueous fractions washed thrice with 20 mL
DCM. The organic fractions were combined, dried with MgSO 4, filtered, and the
solvent was removed under reduced pressure. Column chromatography with 1050% EtOAc:hexane gave the desired product as a white solid (5% yield). 1H NMR
(300 MHz, CDCl3): δ 2.44 (s, 3H), 5.09 (s, 2H), 7.33 (m, 3H), 7.81 (d, 1H, J = 8.33
Hz), 8.56 (s, 1H)

13C

NMR (75 MHz, CDCl3): δ 21.64, 71.00, 120.42, 123.19,

128.04, 129.94, 132.63, 139.50, 145.19, 150.38, 152.35

Molecular formula:

C13H12BrNO3S

Z3.5 (47.5 mg, 0.14 mmol, 1.0 equiv) and NaN3 (27.1 mg, 0.42 mmol, 3.0 equiv)
were dissolved in 10 mL of dry DMF and stirred at 85°C under nitrogen overnight.
Then the reaction was diluted with 60 mL EtOAc and then the solvent was removed
by rotary evaporation. The resulting residue was dissolved in 25 mL EtOAc,
washed with 25 mL of water, then the aqueous layer was extracted three times
with 20 mL of EtOAc. The combined EtOAc fractions were washed five times with
ice water, once with 20 mL of saturated NaCl, dried with MgSO 4, filtered, and the
solvent was removed via rotary evaporation. Azide product Z3.6 was used as a
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yellow-orange solid without further purification for the next reaction (quant).

1H

NMR (300 MHz, CDCl3) δ 4.45 (s, 2H), 7.25 (d, 1H, J = 8.11 Hz, overlaps with
solvent CDCl3 peak), 7.84 (dd, 1H, J = 8.32 Hz, 2.36 Hz), 8.65 (d, 1H, J = 2.26 Hz)
13C

NMR (75 MHz, CDCl3): δ 29.68, 54.99, 119.98, 123.18, 139.57, 150.73, 154.29

Molecular formula: C6H5BrN4
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Spectrum 1: 1H NMR (300 MHz, CDCl3) Compound Z1.1
77

Spectrum 2: 13C NMR (75 MHz, CDCl3) Compound Z1.1
78

Spectrum 3: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.1 [M+1] predicted:
224.09173 [M+1] found: 224.08598
79

Spectrum 4: 1H NMR (300 MHz, CDCl3) Compound Z1.2
80

Spectrum 5: 13C NMR (75 MHz, CDCl3) Compound Z1.2
81

Spectra 6: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.2 [M+1] predicted: 180.06552
[M+1] found: 180.09109
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Spectrum 7: 1H NMR (300 MHz, CDCl3) Compound Z1.3
83

Spectra 8: 13C NMR (75 MHz, CDCl3) Compound Z1.
84

Spectrum 9: Mass specturm (Q-Star XL quadrupole time-of-flight hybrid mass
spectrometer) Compound Z1.3 [M+1] predicted: 507.22381 [M+1] found:
507.233
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Spectrum 10: 1H NMR (300MHz, CDCl3) ZnR1. The aromatic region is muted in CDCl3
86

Spectrum 11: 1H NMR (300 MHz, CDCl3/MeOD) Compound ZnR1. The alkyl region integrates higher than the
aromatic region (polar headgroup) as is common with lipid samples in NMR analysis.
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Spectrum 12: Mass specturm (Q-Star XL quadrupole time-of-flight hybrid mass
spectrometer) Compound ZnR1. [M+Na] predicted: 946.72321 [M+Na] found:
946.7208

88

Spectrum 13: 1H NMR (300 MHz, CDCl3) Compound Z1.4
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Spectrum 14: 13C NMR: (75 MHz, CDCl3) Z1.4
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Spectrum 15: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.4 [M+1] predicted:
182.08117 [M+1] found:182.21761
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Spectrum 16: 1H NMR (300 MHz, CDCl3) Compound Z1.5
92

Spectrum 17: 13C NMR (75 MHz, CDCl3) Compound Z1.5
93

Spectrum 18: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.5 [M+1] predicted:
243.99677, 245.99472 [M+1] found: 243.99381, 245.98980
94

Spectrum 19: 1H NMR (300 MHz, CDCl3) Compound Z1.6
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Spectrum 20: 13C NMR (75 MHz, CDCl3) Compound Z1.6
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Spectrum 21: 1H NMR (300 MHz, CDCl3) Compound Z1.7
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Spectrum 21:

13C

NMR (75 MHz, CDCl3) Compound Z1.7
98

Spectrum 23: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.7 [M+1] predicted:
207.08765 [M+1] found: 207.09040
99

Spectrum 24: 1H NMR (300 MHz, MeOD) Compound Z1.8
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Spectrum 25: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.8 [M+1] predicted:
181.09715 [M+1] found: 181.10196
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Spectrum 26: 1H NMR (300 MHz, MeOD) Compound Z1.10
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Spectrum 27: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.10 [M+1] predicted:
154.04987 [M+1] found: 154.04561
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Spectrum 28: 1H NMR (300 MHz, CDCl3) Compound Z2.1
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Spectrum 29:

13C

NMR (300 MHz, CDCl3) Compound Z2.1
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Spectrum 30: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z2.1 [M+1] predicted:
526.88991, 528.88787 [M+1] found: 526.91788, 528.83407
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Spectrum 31: 1H NMR (300 MHz, CDCl3) Compund ZnR2.2
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Spectrum 32:

13C

NMR (75 MHz, CDCl3) Compund ZnR2.2
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Spectrum 33: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compund ZnR2.2 [M+1] predicted:
621.48907 [M+1] found: 621.43042
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Spectrum 34: 1H NMR (300 MHz, CDCl3) Compound Z2.2
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Spectrum 35: 13C NMR (75 MHz, CDCl3) Compound Z2.2
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Spectra 36: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compund Z2.2 [M+1] predicted: 272.20089
[M+1] found: 272.80493
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Spectrum 37: 1H NMR (300 MHz, CDCl3) Compound Z2.3
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Spectrum 38: 1H NMR (300 MHz, CDCl3) Compound Z3.1
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Spectrum 39: 13C NMR (75 MHz, CDCl3) Compound Z3.1
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Spectrum 40: 1H NMR (300 MHz, CDCl3) Compound Z3.2
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Spectrum 41: 13C NMR (75 MHz, CDCl3) Compound Z3.2
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Spectrum 42: 1H NMR (300 MHz, CDCl3) Compound Z3.5
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Spectrum 43: 13C NMR (75 MHz, CDCl3) Compound Z3.5
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Spectrum 44: 1H NMR (300 MHz, CDCl3) Compound Z3.6
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Spectrum 45: 13C NMR (75 MHz, CDCl3) Compound Z3.6
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